



(51) International Patent Classification:

C08G 69/10 (2006.01) *A61K 38/16* (2006.01)
C08G 69/48 (2006.01) *A61K 47/42* (2006.01)
A61K 39/44 (2006.01) *G01N 33/68* (2006.01)

(21) International Application Number:

PCT/US2016/023428

(22) International Filing Date:

21 March 2016 (21.03.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/136,405 20 March 2015 (20.03.2015) US

(71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (US).

(72) Inventors: **DEMING, Timothy, J.**; 1161 Amherst Avenue #301, Los Angeles, CA 90049 (US). **GHARAKHANIAN, Eric, G.**; 1443 Barry Avenue #106, Los Angeles, CA 90025 (US).

(74) Agents: **HALSTEAD, David** et al.; Foley Hoag LLP, Seaport West, 155 Seaport Blvd, Boston, MA 02210-2600 (US).


(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: POLYPEPTIDES, PEPTIDES, AND PROTEINS FUNCTIONALIZED BY ALKYLATION OF THIOETHER GROUPS VIA RING-OPENING REACTIONS

FIG. 1



(57) Abstract: Some embodiments of the invention involve methods for introduction of various functional groups onto polypeptides, peptides and proteins by alkylation of thioether (a.k.a. sulfide) groups by ring opening reactions, creating new compositions of matter that may be useful for medical therapeutic or diagnostic applications. The thioether groups may either be present in the polypeptides, or may be added to polypeptides by chemical modification, such as by alkylation of thiol (sulfhydryl) groups.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). **Published:**

— *with international search report (Art. 21(3))*

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

**POLYPEPTIDES, PEPTIDES, AND PROTEINS FUNCTIONALIZED BY
ALKYLATION OF THIOETHER GROUPS VIA RING-OPENING REACTIONS**

Related Applications

5 This application claims the benefit of priority to United States Provisional Patent Application serial number 62/136,405, filed March 20, 2015, the contents of which are hereby incorporated by reference.

Government Support

10 This invention was made with government support under DMR1308081 and MSN1412367 awarded by the National Science Foundation. The government has certain rights in the invention.

Background


15 The development of robust methods for facile synthesis of well-defined functional polymers is an ongoing challenge. To circumvent the common incompatibility of reactive side-chain functional groups with polymerization chemistries, there has been considerable effort to develop selective and efficient methods for post-polymerization modification. This is especially true for synthesis of functional polypeptides, which are desirable as mimics of post-translationally
20 modified proteins and for uses in biological and medical applications. Consequently, a variety of precursor polypeptides, and their reactions with functional molecules, have been reported in recent years. Previous efforts have reported the reaction of methionine (Met) residues with alkylating agents as an efficient means to prepare functional polypeptides, which utilizes an inexpensive amino acid precursor and is broad in scope. In those systems, some functional groups can be
25 installed using commercial reagents in water, while others require use of stoichiometric silver salts or preparation of reactive alkyl triflates and anhydrous conditions.

 In addition, many of the activating groups in these examples (i.e. carbonyl, alkyne, aryl), also result in the product sulfonium ions that are unstable toward nucleophiles. These unstable sulfonium products often undergo dealkylation. While such reversibility is desirable for temporary
30 modifications, the ability to prepare permanently functionalized materials under mild conditions is also important for many uses.

There exists a need for improved, efficient, general methods of introducing a wide range of functional groups onto polypeptides. Of specific interest are chemoselective reactions that exhibit high yields in protic solvents.

5 Summary

In some embodiments, the invention relates to a compound of Formula I:



Formula I

wherein, independently for each occurrence,

10 R^1 is H or alkyl;

R^2 is alkyl;

R^3 is H or substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido;

m is 1-200, inclusive;

n is 1-4, inclusive;


20 A^1 is H, an amine protecting group, a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein;

A^2 is OH, -O-(a carboxylate protecting group), a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein; and

X is a monovalent anion.


25 In certain embodiments, the invention relates to any of the compounds described herein, wherein R^3 is -L-halo, -L-azide, -L-NHR¹, -L-NR¹-TFA, -L-NR¹-C(O)-O-alkyl, -L-NR¹-C(O)-CH₂-NR¹-TFA, -L-O-CH₂-CH=CH₂, -L-O-CH₂CCH₃, -L-O-alkyl, -L-O-C(O)-alkyl, -L-P(O)(O-alkyl)₂, -L-P(O)(OH)₂, -L-O-C(O)-C(halo)(alkyl)₂, -L-CH₂-P(O)(O-alkyl)₂, -L-

CH₂-P(O)(OH)₂, -L-O-CH₂CH-(C(O)NR¹-alkyl)(NR¹-TFA), -L-O-CH₂CH-(C(O)OR¹)(NR¹-TFA), -L-OCH₂-C(O)-OR¹, -L-CH-(CO₂-alkyl)₂, -L-CH-(CO₂H)₂, -L-SO₂(O-alkyl), -L-



5 10.

In some embodiments, the invention relates to a peptide, an oligopeptide, a polypeptide, or a protein, wherein the peptide, oligopeptide, polypeptide, or protein comprises substructure I



Substructure I

10 wherein,

R¹ is H or alkyl;

R² is alkyl;



R³ is H or substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted
 15 heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido;

n is 1-4, inclusive; and

X is a monovalent anion.

20 In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein R³ is -L-halo, -L-azide, -L-NHR¹, -L-NR¹-TFA, -L-NR¹-C(O)-O-alkyl, -L-NR¹-C(O)-CH₂-NR¹-TFA, -L-O-CH₂-CH=CH₂, -L-O-


CH₂CCH, -L-O-alkyl, -L-O-C(O)-alkyl, -L-P(O)(O-alkyl)₂, -L-P(O)(OH)₂, -L-O-C(O)-C(halo)(alkyl)₂, -L-CH₂-P(O)(O-alkyl)₂, -L-CH₂-P(O)(OH)₂, -L-O-CH₂CH-(C(O)NR¹-alkyl)(NR¹-TFA), -L-O-CH₂CH-(C(O)OR¹)(NR¹-TFA), -L-OCH₂-C(O)-OR¹, -L-CH-(CO₂-



L is a bond or $-(\text{OCH}_2\text{CH}_2)_x-$, and x is 1-10.

In some embodiments, the invention relates to a process for chemically modifying a peptide, oligopeptide, polypeptide, or protein by alkylation of one or more thioether groups, comprising the steps of:

10 contacting a compound of formula II with an aqueous or polar organic solvent



Formula II,

wherein, independently for each occurrence,

R¹ is H or alkyl;

15 R^2 is alkyl;


m is 1-200, inclusive;

n is 1-4, inclusive;

A¹ is H, an amine protecting group, a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein;

20 A² is OH, -O-(a carboxylate protecting group), a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein;

adding a compound of formula III



Formula III


wherein, independently for each occurrence,

R^3 is H or substituted or unsubstituted amino, substituted or unsubstituted alkyl,

5 substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido; and


reacting the compound of formula II with the compound of formula III, thereby creating a


10 compound of formula I



Formula I.

In certain embodiments, the invention relates to any of the processes described herein, wherein R^3 is -L-halo, -L-azide, -L-NHR¹, -L-NR¹-TFA, -L-NR¹-C(O)-O-alkyl, -L-NR¹-C(O)-CH₂-NR¹-TFA, -L-O-CH₂-CH=CH₂, -L-O-CH₂CCH₃, -L-O-alkyl, -L-O-C(O)-alkyl, -L-P(O)(O-alkyl)₂, -L-P(O)(OH)₂, -L-O-C(O)-C(halo)(alkyl)₂, -L-CH₂-P(O)(O-alkyl)₂, -L-CH₂-P(O)(OH)₂, -L-O-CH₂CH-(C(O)NR¹-alkyl)(NR¹-TFA), -L-O-CH₂CH-(C(O)OR¹)(NR¹-TFA), -L-OCH₂-C(O)-OR¹, -L-CH-(CO₂-alkyl)₂, -L-CH-(CO₂H)₂, -L-SO₂(O-alkyl), -L-SO₂(O-aryl), -





10.

In certain embodiments, the invention relates to compound formed by any of the processes described herein.

5

Brief Description of the Figures

Figure 1 depicts a schematic representation of the alkylation of **M₆₀** with epoxides in acetic acid, 37 °C for 24–48 h followed by counterion exchange. Yield is total isolated yield of completely functionalized polypeptide, except for **9**, **10**, and **11**. a = Percent modification for incomplete functionalizations are in parentheses.

10

Figure 2 depicts a schematic representation of the alkylation of **M₆₀** with epoxides containing an oxoethylene spacer (red) in acetic acid, 37 °C for 36 h followed by ion exchange. Yield is total isolated yield of completely functionalized polypeptide. a = Sulfonate partially deprotected under reaction conditions. b = Yield is of fully deprotected glycopolypeptide.

15

Figure 3 depicts a schematic representation of dealkylation studies on sulfonium **M₆₀** polymers.

Figure 4A shows a reaction scheme for alkylation of PHCKRM with glycidyl azide.

Figure 4B shows a ESI-MS spectrum of PHCKRM with the $[\text{M} + \text{H}]^+$ and $[\text{M} + \text{Na}]^+$ peaks labeled.

20

Figure 4C shows a ESI-MS spectrum of the product after alkylation showing **18**, $[\text{MR}]^+$, as well as the characteristic $[\text{M-RSCH}_3]^+$ fragment.

Figure 5A shows the full ESI-MS data for **PHCKRM**, with $[\text{M}+\text{H}]^+$ (771.1745 m/z) labeled.

Figure 5B shows the full ESI-MS data after alkylation of **PHCKRM** with glycidyl azide to give product **18** $[\text{MR}]^+$ and the characteristic $[\text{M-RSCH}_3]^+$ fragment, which are both labeled (870.1824 & 723.1735 m/z, respectively).

25

Figure 6A depicts a schematic representation of an alkylation reaction of the invention.

Figure 6B tabulates the structures of various compounds of the invention and epoxides used to synthesize them using the reaction from **Figure 6A**.

Description

5 *Overview*

In certain embodiments, the invention relates to a method of Met alkylation using epoxides - an efficient, general method to introduce a wide range of functional groups onto polypeptides. These functionalizations are notable since they can be conducted in wet protic media and are chemoselective, they utilize stable, easily accessible epoxide alkylating agents, and they allow
10 facile incorporation of an unprecedented range of functional groups onto polypeptides using stable linkages.

Some embodiments of the invention involve methods for introduction of various functional groups onto polypeptides, peptides and proteins by alkylation of thioether (a.k.a. sulfide) groups by ring opening reactions, creating new compositions of matter that may be useful for medical
15 therapeutic or diagnostic applications. The thioether groups may either be present in the polypeptides, or may be added to polypeptides by chemical modification, such as by alkylation of thiol (sulfhydryl) groups. These methods are general and can be applied to a wide range of different peptidic materials, including polypeptides, peptides and proteins. Certain embodiments of this invention relate to the modification of polypeptides via the thioether groups naturally present in
20 methionine or in S-alkyl cysteine residues. A variety of new functionalities have been added to polypeptides via this process, including alkenes, alkynes, sulfonates, phosphonates, carbohydrates, amines, and alkyl halides, creating many new functional polypeptides, each of which are new compositions of matter. This alkylation process is a simple one-step modification and thus an economical way to prepare polypeptides with complex functionality that have potential use in
25 applications including therapeutics, antimicrobials, delivery vehicles, coatings, composites, and scaffolds. The chemoselective nature of this reaction also makes it amenable for site-specific modification of peptides and proteins, highly desirable for therapeutic and diagnostic uses of these materials.

Embodiments of the technology described herein provide advantages over similar related
30 technologies in the field. By way of example, some advantages include (but are not limited to) allowing formation of stable functional polypeptide products through use of more readily available cyclic alkylating agents (e.g., epoxides, aziridines, oxazolines, sultones). This allows the

functionalization to be conducted in protic media, and avoids the need for use of stoichiometric silver salts or preparation of unstable alkyl triflates.

In some embodiments, the invention relates to the post-functionalization of poly(methionine) (poly(Met)). The functional groups introduced by the methods of the invention can be used to control polymer conformation. Numerous alkylating reagents have been found to react with poly(Met), allowing access to sulfonium derivatives functionalized with oligoethylene glycol (OEG), sugars, and other functional groups. These polymers display a range of tunable cloud points.


In addition, methodology has been developed for efficient alkylation of methionine residues using epoxides as a general strategy to introduce a wide range of functional groups onto polypeptides. Use of a spacer between epoxide and functional groups further allows addition of sterically demanding functionalities. Contrary to other methods to alkylate methionine residues, epoxide alkylations allow the reactions to be conducted in wet protic media and give sulfonium products that are stable against dealkylation. These functionalizations are notable since they are chemoselective, utilize stable and readily available epoxides, and allow facile incorporation of an unprecedented range of functional groups onto simple polypeptides using stable linkages.

For example, ethylene oxide (EO) reacts with many functional amino acids, including Met residues, to give stable β -hydroxyethyl sulfonium products (Figure 1). Similar to reactions of alkyl halides with Met, the reaction of EO with proteins was observed to be selective for Met residues at pH < 3, where all other nucleophilic functional groups are protonated and unreactive. Subsequent studies, utilizing N-protected Met amino acid, showed that substituted epoxides, such as propylene oxide and tert-butyl glycidyl ether, also react with Met to give sulfonium ions that are stable to acid and mild base. In these cases, the sulfur of Met adds primarily to the least hindered side of the epoxide to give the β -alkyl- β -hydroxyethyl sulfonium (Figure 1). Figure 1 shows alkylation of M₆₀ with epoxides in acetic acid, 37 °C for 24-48 h followed by counterion exchange. Yield is total isolated yield of completely functionalized polypeptide. a = Percent functionalization is reported instead of yield. These data show that addition of epoxides to Met residues is promising as a potentially chemoselective reaction to prepare stable sulfonium products, even in protic media. Since a large variety of epoxides are either commercially available or readily prepared, we sought to further develop this reaction as a general means to synthesize a broad range of functional and stable Met derivatives under mild conditions.

To test epoxide reactivity with polypeptides, we reacted a 60-mer Met polymer, M_{60} , with EO, propylene oxide or glycidyl azide under different conditions in protic media. It was observed that that highest degrees of functionalization and shortest reaction times were obtained using a small excess of epoxide (1.5 to 3 equivalents) in glacial AcOH at 37 °C (Figure 1). The reaction is significantly faster under acidic conditions compared to neutral pH, although some epoxide is consumed by the acidic solvent, hence the use of 3 equivalents of epoxide per Met residue. If the epoxide is added over time (e.g., in stages), quantitative functionalization can also be obtained using 1.5 equivalents of epoxide. High degrees of functionalization were also obtained with epoxides containing other desirable functional groups, such as protected amine, alkyl chloride, alkene, alkyne, and oligoethyleneglycol (Figure 1). Many of these are reactive groups that can be utilized for secondary functionalization using a diverse range of chemistries. The resulting sulfoniums were all highly water soluble and exclusively contained the alkyl substituents at the β -position except in the case of **2**, which showed a trace of the α -alkylation product due to low steric demand of the substrate. Potential advantages of this methodology can be seen by the introduction of azido groups via an epoxide in wet media, which previously required use of an azido triflate in anhydrous solvent.

Attempts to functionalize M_{60} with more sterically demanding epoxides, including those containing monosaccharides, ATRP initiating groups, and phosphonates, demonstrated that that complete conversion of all Met residues to sulfoniums could not be readily obtained (Figure 1). Such functional groups are difficult to introduce onto polypeptides by other methods, and are useful for a variety of applications including binding to biomolecules, synthesis of hybrid copolymers, or mimicking biomineralization processes. The inability to completely functionalize poly(Met) polymers with bulky epoxides was likely due to crowding of neighboring groups on the polymer backbone preventing further functionalization. To circumvent this issue, functional epoxides containing oxoethylene spacers that increased the distance between functional groups and the epoxides were prepared (Figure 2). Figure 2 shows alkylation of M_{60} with epoxides containing an oxoethylene spacer (red) in acetic acid, 37 °C for 36 h followed by ion exchange. Yield is total isolated yield of completely functionalized polypeptide. a = Sulfonate partially deprotected under reaction conditions. b = Yield is of fully deprotected glycopolypeptide. With these longer tethers, quantitative alkylations of M_{60} polymers with a wide array of large functional groups were achieved, allowing facile preparation of polypeptides containing a variety of unprecedented or difficult to introduce functional groups such as sulfonate, phosphonate, and malonate (Figure 2).


These polybetaines should possess interesting properties potentially useful for binding metal ions or creating non-fouling surfaces.




Some of the functional epoxides above required use of protecting groups during synthesis.

- 5 In general, the sulfonium products exhibited sufficient stability to allow full removal of these protecting groups after alkylation without loss of the functional groups (Scheme 1). Scheme 1 shows removal of protecting groups from representative functionalized M_{60} polymers. The sulfonium products were also stable toward secondary bio-orthogonal functionalizations, such as azide-alkyne cycloadditions (equation 1). To study the stability of the sulfonium M polymers in
- 10 more detail, select group of samples were subjected to different aqueous conditions (Figure 3). Figure 3 shows dealkylation studies on sulfonium M_{60} polymers. Methylated (M^{Me}) and benzylated (M^{Bn}) samples were chosen as points of reference since these have been shown respectively to be unreactive and highly reactive towards dealkylation by nucleophiles. Polypeptides 4 (M^{N_3}) and 8 (M^{EG}), prepared by alkylation with functional epoxides, were found to display good stability in
- 15 aqueous buffers ranging in pH from 5 to 9. These polymers were also quite stable against

dealkylation by the potent nucleophile 2-mercaptopyridine. These results show that the polysulfonium structures obtained from epoxide alkylation are significantly more stable than those prepared from activated alkyl halides (e.g., benzyl bromide).



5 To test the chemoselectivity for epoxide alkylation of Met over other nucleophilic functional groups, a statistical copolymer of Met and L-lysine was prepared and its alkylation was studied. Lysine was selected as a competing nucleophile since it is the most abundant nucleophile found in proteins, it is more widely used in synthetic polypeptides compared to histidine or cysteine, and it is known to compete with thiol and imidazole groups in protein alkylations. Similar
10 to results obtained in other Met alkylations, we found that the Met residues in the copolymer could be alkylated chemoselectively with glycidyl azide in acidic media in the presence of a fourfold excess of amine groups (equation 2).




15 For a more demanding test of chemoselectivity, we attempted to alkylate only the Met residues in the antioxidant peptide PHCKRM, which also contains highly nucleophilic histidine, cysteine and lysine residues (Figure 4). Figure 4 shows chemoselective alkylation of PHCKRM. Figure 4A shows the reaction scheme for alkylation of PHCKRM with glycidyl azide. Figure 4B shows the ESI-MS spectrum of PHCKRM with the $[M+H]^+$ and $[M+Na]^+$ peaks labeled. Figure

4C shows the product after alkylation showing **18**, $[\text{MR}]^+$, as well as the characteristic $[\text{M-RSCH}_3]^+$ fragment. Treatment of PHCKRM with glycidyl azide in glacial AcOH gave high conversion to a single product (**18**), where only the Met residue was alkylated. The identity of **18** was determined using ESI-MS (Figure 4A, B, and C, and Figure 5A and B), where the parent ion (MR^+ , R = 3-azido-2-hydroxypropyl group) showed addition of only a single 100 Da 3-azido-2-hydroxypropyl group to the peptide. Figure 5A shows full ESI-MS data for **PHCKRM**, with $[\text{M+H}]^+$ (771.1745 m/z) labeled. Figure 5B shows full ESI-MS data after alkylation of **PHCKRM** with glycidyl azide to give product **18** $[\text{MR}]^+$ and the characteristic $[\text{M-RSCH}_3]^+$ fragment, which are both labeled (870.1824 & 723.1735 m/z, respectively). The additional presence of a single dominant fragment corresponding to the loss of the thioether RSCH_3 , which is commonly observed in MS analysis of Met sulfonium ions, confirmed that alkylation was only occurring at the Met residue. These results also demonstrate that, in addition to polypeptides, peptides can be chemoselectively modified in high yields at Met residues via epoxide alkylation at low pH.

The alkylation of Met residues in polypeptides using functional epoxides was developed to give high yields of fully functionalized Met sulfonium containing materials, which were found to possess high water solubility and good stability against dealkylation. The epoxide reagents were optimized to provide chemoselective functionalization of Met, even when multiple sterically demanding functional groups were added to polypeptides. The methods described in this sample embodiment provide a simple solution for preparation of a diverse array of functional polypeptides in wet conditions using readily available or easily prepared reagents. Since M polymers are readily prepared from an inexpensive amino acid without need of protecting groups, this provides an economical approach to functional polypeptides will allow their use in an expanded array of applications.

Exemplary Compounds

In certain embodiments, the invention relates to a compound of Formula I:



Formula I

5 wherein, independently for each occurrence,

R^1 is H or alkyl;

R^2 is alkyl;

R^3 is H or substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted
 10 heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido;

m is 1-200, inclusive;

n is 1-4, inclusive;

15 A^1 is H, an amine protecting group, a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein;

A^2 is OH, -O-(a carboxylate protecting group), a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein; and

X is a monovalent anion.

20 In certain embodiments, the invention relates to any of the compounds described herein, wherein R^1 is preferably H.

In certain embodiments, the invention relates to any of the compounds described herein, wherein R^1 is alkyl, for example, methyl or ethyl.

In certain embodiments, the invention relates to any of the compounds described herein,
 25 wherein R^2 is methyl, ethyl, n-propyl, or n-butyl; preferably, R^2 is methyl.

In certain embodiments, the invention relates to any of the compounds described herein, wherein R^3 is substituted or unsubstituted amino, substituted or unsubstituted alkyl,


substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido.

5 In certain embodiments, the invention relates to any of the compounds described herein, wherein R³ is unsubstituted amino, unsubstituted alkyl, unsubstituted alkyloxy, azido, unsubstituted aryl, unsubstituted heteroaryl, halo, unsubstituted allyloxy, unsubstituted alkylcarbonyloxy, unsubstituted phosphonate, unsubstituted carbamate, or unsubstituted amido.

10 In certain embodiments, the invention relates to any of the compounds described herein, wherein R³ is substituted amino, substituted alkyl, substituted alkyloxy, substituted aryl, substituted heteroaryl, substituted allyloxy, substituted alkylcarbonyloxy, substituted phosphonate, substituted carbamate, or substituted amido.

In certain embodiments, the invention relates to any of the compounds described
15 herein, wherein R³ is substituted alkyloxy, for example, heterocycloalkyloxy, phosphonate-
substituted alkyloxy, acyloxyalkyloxy, aminoalkyloxy, aminoalkylamidoalkyloxy, or
alkyloxycarbonylalkyloxy.

In certain embodiments, the invention relates to any of the compounds described herein, wherein R³ is -L-halo, -L-azide, -L-NHR¹, -L-NR¹-TFA, -L-NR¹-C(O)-O-alkyl, -L-NR¹-C(O)-CH₂-NR¹-TFA, -L-O-CH₂-CH=CH₂, -L-O-CH₂CCH, -L-O-alkyl, -L-O-C(O)-alkyl, -L-P(O)(O-alkyl)₂, -L-P(O)(OH)₂, -L-O-C(O)-C(halo)(alkyl)₂, -L-CH₂-P(O)(O-alkyl)₂, -L-CH₂-P(O)(OH)₂, -L-O-CH₂CH-(C(O)NR¹-alkyl)(NR¹-TFA), -L-O-CH₂CH-(C(O)OR¹)(NR¹-TFA), -L-OCH₂-C(O)-OR¹, -L-CH-(CO₂-alkyl)₂, -L-CH-(CO₂H)₂, -L-SO₂(O-alkyl), -L-



10.

In certain embodiments, the invention relates to any of the compounds described herein, wherein x is 1, 2, 3, 4, 5, or 6; preferably, x is 2, 3, or 4.

In certain embodiments, the invention relates to any of the compounds described herein, wherein m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100. In some embodiments, m is 1. In other embodiments, m is 60.

In certain embodiments, the invention relates to any of the compounds described herein, wherein n is 1, 2, or 3; preferably, n is 2.

In certain embodiments, the invention relates to any of the compounds described herein, wherein A¹ is an amine protecting group selected from an *N,O*-acetal, allyloxycarbonyl (Aloc), benzyl (Bn), benzyloxycarbonyl (Cbz), benzyloxymethyl (BOM), *t*-butoxycarbonyl (Boc), *t*-butyldimethylsilyl (TBDMS), *t*-butyldiphenylsilyl (TBDPS), diphenylmethyl, diphenylmethylen, ethoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), *p*-methoxybenzyl (PMB), methoxycarbonyl, methoxymethyl (MOM), *p*-methoxyphenyl (PMP), *p*-nitrocinnylmethoxycarbonyl (Noc), tosyl (Ts), 2-tosylethoxycarbonyl (Tsoc), 2,2,2-trichloroethoxycarbonyl (Troc), trifluoroacetyl, triisopropylsilyl (TIPS), trimethylsilyl (TMS), 2-(trimethylsilyl)ethoxycarbonyl (Teoc), 2-(trimethylsilyl)ethoxymethyl (SEM), or trityl (Tr).

In certain other embodiments, the invention relates to any of the compounds described herein, wherein A¹ is a protein, preferably an antibody.

In some embodiments, the invention relates to any of the compounds described herein, wherein A² is an -O-(carboxylate protecting group), and the carboxylate protecting group is selected from allyl, benzyl, benzyloxymethyl (BOM), *t*-Bu, *t*-butyldimethylsilyl (TBDMS), *t*-butyldiphenylsilyl (TBDPS), diphenylmethyl, 9-fluorenylmethyl (Fm), 2-methoxyethoxymethyl (MEM), methoxymethyl (MOM), *p*-nitrobenzyl (PNB), an ester, a 1,3-oxazoline, pivaloyloxymethyl (Pom), 2-tosylethyl (TSE), 2,2,2-trichloroethyl (TCE), triethylsilyl (TES), trimethylsilyl (TMS), 2-(trimethylsilyl)ethoxymethyl (SEM), or 2-(trimethylsilyl)ethyl (TMSE).

In some other embodiments, the invention relates to any of the compounds described herein, wherein A² is a protein, preferably an antibody.

In certain embodiments, the invention relates to any of the compounds described herein, wherein A¹ or A² is methionine, or A¹ or A² is a peptide comprising a methionine residue, an oligopeptide comprising a methionine residue, a polypeptide comprising a methionine residue, or a protein comprising a methionine residue.


5 In other embodiments, the invention relates to any of the compounds described herein, wherein A¹ or A² is cysteine, or A¹ or A² is a peptide comprising a cysteine residue, an oligopeptide comprising a cysteine residue, a polypeptide comprising a cysteine residue, or a protein comprising a cysteine residue.

10 In certain embodiments, the invention relates to any of the compounds described herein, wherein the compound of formula I is an antibody.

In some embodiments, the invention relates to any of the compounds described herein, for example, in a scheme, an equation, an example, or a figure.

Exemplary peptides, oligopeptides, polypeptides, and proteins

15 In certain embodiments, the invention relates to a peptide, an oligopeptide, a polypeptide, or a protein, wherein the peptide, oligopeptide, polypeptide, or protein comprises substructure I



Substructure I

wherein,

20 R¹ is H or alkyl;

R² is alkyl;

R³ is H or substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido;

n is 1-4, inclusive; and

X is a monovalent anion.

In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein the peptide, oligopeptide, polypeptide, or protein comprises a plurality of substructures I.

5 In certain embodiments, the invention relates any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein R^1 is preferably H.

In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein R^1 is alkyl, for example, methyl or ethyl.

10 In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein R^2 is methyl, ethyl, n-propyl, or n-butyl; preferably, R^2 is methyl.

In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein R^3 is substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or
15 unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido.


In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein R^3 is unsubstituted amino, unsubstituted
20 alkyl, unsubstituted alkyloxy, azido, unsubstituted aryl, unsubstituted heteroaryl, halo, unsubstituted allyloxy, unsubstituted alkylcarbonyloxy, unsubstituted phosphonate, unsubstituted carbamate, or unsubstituted amido.


In certain embodiments, the invention relates to any of the compounds described herein, wherein R^3 is substituted amino, substituted alkyl, substituted alkyloxy, substituted
25 aryl, substituted heteroaryl, substituted allyloxy, substituted alkylcarbonyloxy, substituted phosphonate, substituted carbamate, or substituted amido.

In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein R^3 is substituted alkyloxy, for example, heterocycloalkyloxy, phosphonate-substituted alkyloxy, acyloxyalkyloxy, aminoalkyloxy,
30 aminoalkylamidoalkyloxy, or alkyloxycarbonylalkyloxy.

In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein R^3 is -L-halo, -L-azide, -L-NHR¹, -L-NR¹-

TFA, $-L-NR^1-C(O)-O\text{-alkyl}$, $-L-NR^1-C(O)-CH_2-NR^1\text{-TFA}$, $-L-O-CH_2-CH=CH_2$, $-L-O-CH_2CCH$, $-L-O\text{-alkyl}$, $-L-O-C(O)\text{-alkyl}$, $-L-P(O)(O\text{-alkyl})_2$, $-L-P(O)(OH)_2$, $-L-O-C(O)-C(\text{halo})(\text{alkyl})_2$, $-L-CH_2-P(O)(O\text{-alkyl})_2$, $-L-CH_2-P(O)(OH)_2$, $-L-O-CH_2CH-(C(O)NR^1\text{-alkyl})(NR^1\text{-TFA})$, $-L-O-CH_2CH-(C(O)OR^1)(NR^1\text{-TFA})$, $-L-OCH_2-C(O)-OR^1$, $-L-CH-(CO_2\text{-alkyl})_2$, $-L-CH-(CO_2H)_2$, $-L-SO_2(O\text{-alkyl})$, $-L-SO_2(O\text{-aryl})$, $-L-SO_3H$,

5 $-L-CH-(CO_2H)_2$, $-L-SO_2(O\text{-alkyl})$, $-L-SO_2(O\text{-aryl})$, $-L-SO_3H$, ,



L is a bond or $-(OCH_2CH_2)_x-$, and x is 1-10.

In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein x is 1, 2, 3, 4, 5, or 6; preferably, x is 2, 3, or 4.

In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100. In some embodiments, m is 1. In other embodiments, m is 60.


In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein, wherein n is 1, 2, or 3; preferably, n is 2.

In certain embodiments, the invention relates to any of the peptides, oligopeptides, polypeptides, or proteins described herein.

Exemplary Methods

In certain embodiments, the invention relates to a method for chemically modifying a peptide, oligopeptide, polypeptide, or protein by alkylation of one or more thioether groups comprising the steps of:

contacting a compound of formula II with an aqueous or polar organic solvent



Formula II,

wherein, independently for each occurrence,

5 R^1 is H or alkyl;

R^2 is alkyl;


m is 1-200, inclusive;

n is 1-4, inclusive;

10 A^1 is H, an amine protecting group, a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein;

A^2 is OH, -O-(a carboxylate protecting group), a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein;

adding a compound of formula III




Formula III

wherein, independently for each occurrence,

15 R^3 is H or substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted
20 alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido; and

reacting the compound of formula II with the compound of formula III, thereby creating a compound of formula I



Formula I.

In certain embodiments, the invention relates to any of the methods described herein, wherein the compound of formula II is suspended in an aqueous or polar organic solvent. In other
 5 embodiments, the compound of formula II is dissolved in an aqueous or polar organic solvent. In even other embodiments, the compound of formula II is mixed with an aqueous or polar organic solvent.

In certain embodiments, the invention relates to any of the methods described herein, wherein R¹ is preferably H.

10 In certain embodiments, the invention relates to any of the methods described herein, wherein R¹ is alkyl, for example, methyl or ethyl.

In certain embodiments, the invention relates to any of the methods described herein, wherein R² is methyl, ethyl, n-propyl, or n-butyl; preferably, R² is methyl.

15 In certain embodiments, the invention relates to any of the methods described herein, wherein R³ is substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido.


20 In certain embodiments, the invention relates to any of the methods described herein, wherein R³ is unsubstituted amino, unsubstituted alkyl, unsubstituted alkyloxy, azido, unsubstituted aryl, unsubstituted heteroaryl, halo, unsubstituted allyloxy, unsubstituted alkylcarbonyloxy, unsubstituted phosphonate, unsubstituted carbamate, or unsubstituted amido.

25 In certain embodiments, the invention relates to any of the methods described herein, wherein R³ is substituted amino, substituted alkyl, substituted alkyloxy, substituted aryl,

substituted heteroaryl, substituted allyloxy, substituted alkylcarbonyloxy, substituted phosphonate, substituted carbamate, or substituted amido.

In certain embodiments, the invention relates to any of the methods described herein, wherein R^3 is substituted alkyloxy, for example, heterocycloalkyloxy, phosphonate-substituted alkyloxy, acyloxyalkyloxy, aminoalkyloxy, aminoalkylamidoalkyloxy, or alkyloxycarbonylalkyloxy.

In certain embodiments, the invention relates to any of the methods described herein, wherein R^3 is -L-halo, -L-azide, -L-NHR¹, -L-NR¹-TFA, -L-NR¹-C(O)-O-alkyl, -L-NR¹-C(O)-CH₂-NR¹-TFA, -L-O-CH₂-CH=CH₂, -L-O-CH₂CCH₃, -L-O-alkyl, -L-O-C(O)-alkyl, -L-P(O)(O-alkyl)₂, -L-P(O)(OH)₂, -L-O-C(O)-C(halo)(alkyl)₂, -L-CH₂-P(O)(O-alkyl)₂, -L-CH₂-P(O)(OH)₂, -L-O-CH₂CH-(C(O)NR¹-alkyl)(NR¹-TFA), -L-O-CH₂CH-(C(O)OR¹)(NR¹-TFA), -L-OCH₂-C(O)-OR¹, -L-CH-(CO₂-alkyl)₂, -L-CH-(CO₂H)₂, -L-SO₂(O-alkyl), -L-SO₂(O-aryl), -



; L is a bond or -(OCH₂CH₂)_x, and x is 1-

In certain embodiments, the invention relates to any of the methods described herein, wherein x is 1, 2, 3, 4, 5, or 6; preferably, x is 2, 3, or 4.

In certain embodiments, the invention relates to any of the methods described herein, wherein m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100. In some embodiments, m is 1. In other embodiments, m is 60.

In certain embodiments, the invention relates to any of the methods described herein, wherein n is 1, 2, or 3; preferably, n is 2.

In certain embodiments, the invention relates to any of the methods described herein, wherein A¹ is an amine protecting group selected from an *N,O*-acetal, allyloxycarbonyl (Aloc), benzyl (Bn), benzyloxycarbonyl (Cbz), benzyloxymethyl (BOM), *t*-butoxycarbonyl (Boc), *t*-butyldimethylsilyl (TBDMS), *t*-butyldiphenylsilyl (TBDPS), diphenylmethyl, 5 diphenylmethyle, ethoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), *p*-methoxybenzyl (PMB), methoxycarbonyl, methoxymethyl (MOM), *p*-methoxyphenyl (PMP), *p*-nitrocinnamylloxycarbonyl (Noc), tosyl (Ts), 2-tosylethoxycarbonyl (Tsoc), 2,2,2-trichloroethoxycarbonyl (Troc), trifluoroacetyl, triisopropylsilyl (TIPS), trimethylsilyl (TMS), 2-(trimethylsilyl)ethoxycarbonyl (Teoc), 2-(trimethylsilyl)ethoxymethyl (SEM), or trityl (Tr).

10 In certain other embodiments, the invention relates to any of the methods described herein, wherein A¹ is a protein, preferably an antibody.

In some embodiments, the invention relates to any of the methods described herein, wherein A² is an -O-(carboxylate protecting group), and the carboxylate protecting group is selected from allyl, benzyl, benzyloxymethyl (BOM), *t*-Bu, *t*-butyldimethylsilyl (TBDMS), 15 butyldiphenylsilyl (TBDPS), diphenylmethyl, 9-fluorenylmethyl (Fm), 2-methoxyethoxymethyl (MEM), methoxymethyl (MOM), *p*-nitrobenzyl (PNB), an ester, a 1,3-oxazoline, pivaloyloxymethyl (Pom), 2-tosylethyl (TSE), 2,2,2-trichloroethyl (TCE), triethylsilyl (TES), trimethylsilyl (TMS), 2-(trimethylsilyl)ethoxymethyl (SEM), or 2-(trimethylsilyl)ethyl (TMSE).

20 In other embodiments, the invention relates to any of the methods described herein, wherein A² is a protein, preferably an antibody.

In certain embodiments, the invention relates to any of the methods described herein, wherein A¹ or A² is methionine, or A¹ or A² is a peptide comprising a methionine residue, an oligopeptide comprising a methionine residue, a polypeptide comprising a methionine residue, 25 or a protein comprising a methionine residue.

In other embodiments, the invention relates to any of the methods described herein, wherein A¹ or A² is cysteine, or A¹ or A² is a peptide comprising a cysteine residue, an oligopeptide comprising a cysteine residue, a polypeptide comprising a cysteine residue, or a protein comprising a cysteine residue.

30 In certain embodiments, the invention relates to any of the methods described herein, wherein the compound of formula II is an antibody.

In certain embodiments, the invention relates to any of the methods described herein, wherein the compound of formula I is an antibody.

In certain embodiments, the invention relates to any of the methods described herein, wherein the pH of the aqueous or polar organic solvent is less than about 3. In other embodiments, the invention relates to any of the methods described herein, wherein the pH of the aqueous or polar organic solvent is about 2.5, about 2.0, about 1.5, about 1.0, or about 0.5.

In certain embodiments, the invention relates to any of the methods described herein, wherein the mole ratio of the compound of formula III to the compound of formula II is from about 5:1 to about 1.5:1, for example, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2.5:1, about 2:1, or about 1.5:1, preferably about 3:1, about 2.5:1, about 2:1, or about 1.5:1.

In certain embodiments, the invention relates to any of the methods described herein, wherein the temperature of the aqueous or polar organic solvent is from about 20 °C to about 40 °C, for example about 30 °C, about 31 °C, about 32 °C, about 33 °C, about 34 °C, about 35 °C, about 36 °C, about 37 °C, about 38 °C, about 39 °C, or about 40 °C, preferably about 37 °C.

In certain embodiments, the invention relates to any of the methods described herein, wherein the aqueous or polar organic solvent is preferably glacial AcOH.

For example, the inventive methods may be used to modify at least one amino acid residue of a peptide, an oligopeptide, a polypeptide, or a protein, regardless of whether the amino acid residue to be modified is found at the N-terminus, the C-terminus, or in the middle of the sequence of amino acids of the peptide, oligopeptide, polypeptide, or protein.

In various embodiments, the invention relates to a compound formed by any of the methods or processes described herein.

Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

The term "heteroatom" is art-recognized and refers to an atom of any element other than carbon or hydrogen. Illustrative heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium.

The term "alkoxy" means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.

5 The term "alkoxycarbonyl" means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, represented by -C(=O)- , as defined herein. Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.

10 The term "alkyl" means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.

15 The term "alkylcarbonyl" as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.

20 The term "alkylcarbonyloxy" and "arylcarbonyloxy" as used herein, means an alkylcarbonyl or arylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy. Representative examples of arylcarbonyloxy include, but are not limited to phenylcarbonyloxy.

25 The term "alkylthio" as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert-butylthio, and hexylthio. The terms "arylthio," "alkenylthio" and "arylakylthio," for example, are likewise defined.

 The term "amido" as used herein, means -NHC(=O)- , wherein the amido group is bound to the parent molecular moiety through the nitrogen. Examples of amido include alkylamido such as $\text{CH}_3\text{C(=O)N(H)-}$ and $\text{CH}_3\text{CH}_2\text{C(=O)N(H)-}$.

30 The term "amino" as used herein, refers to radicals of both unsubstituted and substituted amines appended to the parent molecular moiety through a nitrogen atom. The two groups are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, or

formyl. Representative examples include, but are not limited to methylamino, acetylamino, and acetylmethylamino.

The term "aromatic" refers to a planar or polycyclic structure characterized by a cyclically conjugated molecular moiety containing $4n+2$ electrons, wherein n is the absolute value of an integer. Aromatic molecules containing fused, or joined, rings also are referred to as bicyclic aromatic rings. For example, bicyclic aromatic rings containing heteroatoms in a hydrocarbon ring structure are referred to as bicyclic heteroaryl rings.

The term "aryl," as used herein, means a phenyl group or a naphthyl group. The aryl groups of the invention can be optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, amido, amino, carboxy, cyano, formyl, halo, haloalkoxy, haloalkyl, hydroxyl, hydroxyalkyl, mercapto, nitro, phosphinyl, silyl and silyloxy.

The term "arylene," is art-recognized, and as used herein, pertains to a bidentate moiety obtained by removing two hydrogen atoms of an aryl ring, as defined above.

The term "arylalkyl" or "aralkyl" as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.

The term "carbonyl" as used herein, means a $-C(=O)-$ group.

The term "carboxy" as used herein, means a $-CO_2H$ group.

The term "cyano" as used herein, means a $-CN$ group.

The term "halo" or "halogen" means $-Cl$, $-Br$, $-I$ or $-F$.

The term "haloalkyl" means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.

The term "heterocyclyl", as used herein, include non-aromatic, ring systems, including, but not limited to, monocyclic, bicyclic and tricyclic rings, which can be completely saturated or which can contain one or more units of unsaturation, for the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system) and have 3 to 12 atoms including at least one heteroatom, such as nitrogen, oxygen, or sulfur. For purposes of exemplification,

which should not be construed as limiting the scope of this invention, the following are examples of heterocyclic rings: azepines, azetidiny, morpholinyl, oxopiperidinyl, oxopyrrolidinyl, piperazinyl, piperidinyl, pyrrolidinyl, quinuclidinyl, thiomorpholinyl, tetrahydropyranyl and tetrahydrofuranyl. The heterocyclyl groups of the invention are substituted with 0, 1, 2, 3, 4 or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, amido, amino, carboxy, cyano, formyl, halo, haloalkoxy, haloalkyl, hydroxyl, hydroxyalkyl, mercapto, nitro, phosphinyl, silyl and silyloxy.

The term "heteroaryl" as used herein, include aromatic ring systems, including, but not limited to, monocyclic, bicyclic and tricyclic rings, and have 3 to 12 atoms including at least one heteroatom, such as nitrogen, oxygen, or sulfur. For purposes of exemplification, which should not be construed as limiting the scope of this invention: azaindolyl, benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoxadiazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl, indolinyl, indazolyl, isoindolinyl, isoxazolyl, isothiazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, quinolinyl, quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrahydroindolyl, tetrazolyl, thiadiazolyl, thienyl, thiomorpholinyl, triazolyl or tropanyl. The heteroaryl groups of the invention are substituted with 0, 1, 2, 3, 4 or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, amido, amino, carboxy, cyano, formyl, halo, haloalkoxy, haloalkyl, hydroxyl, hydroxyalkyl, mercapto, nitro, phosphinyl, silyl and silyloxy.

The term "heteroarylene," is art-recognized, and as used herein, pertains to a bidentate moiety obtained by removing two hydrogen atoms of a heteroaryl ring, as defined above.

The term "heteroarylalkyl" or "heteroaralkyl" as used herein, means a heteroaryl, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heteroarylalkyl include, but are not limited to, pyridin-3-ylmethyl and 2-(thien-2-yl)ethyl.

The term "hydroxy" as used herein, means an -OH group.

The term "hydroxyalkyl" as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein.

Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.

The term "mercapto" as used herein, means a -SH group.

The term "nitro" as used herein, means a -NO₂ group.

5 The term "silyl" as used herein includes hydrocarbyl derivatives of the silyl (H₃Si-) group (i.e., (hydrocarbyl)₃Si-), wherein a hydrocarbyl groups are univalent groups formed by removing a hydrogen atom from a hydrocarbon, e.g., ethyl, phenyl. The hydrocarbyl groups can be combinations of differing groups which can be varied in order to provide a number of silyl groups, such as trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-
10 butyldimethylsilyl (TBS/TBDMS), triisopropylsilyl (TIPS), and [2-(trimethylsilyl)ethoxy]methyl (SEM).

The term "silyloxy" as used herein means a silyl group, as defined herein, is appended to the parent molecule through an oxygen atom.

15 The definition of each expression, e.g., alkyl, m, n, and the like, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

20 The terms triflyl, tosyl, mesyl, and nonaflyl are art-recognized and refer to trifluoromethanesulfonyl, *p*-toluenesulfonyl, methanesulfonyl, and nonafluorobutanesulfonyl groups, respectively. The terms triflate, tosylate, mesylate, and nonaflate are art-recognized and refer to trifluoromethanesulfonate ester, *p*-toluenesulfonate ester, methanesulfonate ester, and nonafluorobutanesulfonate ester functional groups and molecules that contain said groups, respectively.

25 The abbreviations Me, Et, Ph, Tf, Nf, Ts, and Ms represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, nonafluorobutanesulfonyl, *p*-toluenesulfonyl and methanesulfonyl, respectively. A more comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears in the first issue of each volume of the *Journal of Organic Chemistry*; this list is typically presented in a table entitled *Standard List of Abbreviations*.

30 Certain compounds contained in compositions of the invention may exist in particular geometric or stereoisomeric forms. In addition, polymers of the invention may also be optically active. The invention contemplates all such compounds, including cis- and trans-isomers, *R*- and *S*-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric

carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.

If, for instance, a particular enantiomer of compound of the invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.

It will be understood that "substitution" or "substituted with" includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.

The term "substituted" is also contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above. The permissible substituents may be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.

The phrase "protecting group" as used herein means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P.G.M. *Protective Groups in Organic Synthesis*, 2nd ed.; Wiley: New York, 1991). Protected forms of the inventive compounds are included within the scope of this invention.

For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.

Exemplification

5 The following examples include experimental procedures and spectral data for sample compounds, procedures for alkylation reactions, and methods for stability studies.


General Materials and Methods

Unless otherwise stated, all polymer functionalization reactions were performed in glass vials, under ambient atmosphere. Small molecule reactions were performed under N₂ using oven
10 dried glassware. Reactions at elevated temperature were controlled using a Corning PC 420D thermostated hotplate equipped with a thermocouple probe. Room temperature reactions were performed at ca. 20 °C ambient temperature. THF and CH₂Cl₂ were degassed by sparging with N₂ and dried by passing through alumina columns. Commercial anhydrous DMF was used as received. Fisher ACS grade glacial AcOH was used as received. The **PHCKRM** peptide was
15 obtained from NeoBioLab and was reported 96.7% pure. Poly(*S*-methylmethionine sulfonium chloride), **M^{Me}**, and poly(*S*-benzylmethionine sulfonium chloride), **M^{Bn}**, were prepared as previously described.¹⁵ Allyl alcohol was dried by storing over 3 Å molecular sieves. All other reagents were used as received. Dialysis was performed using deionized water (18.2 MΩ-cm) prepared by passing in-house deionized water through a Millipore Milli-Q Biocel A10 unit. In all
20 other cases, in-house reverse osmosis purified water was used. Thin-layer chromatography was performed with EMD gel 60 F254 plates (0.25 mm thickness) and visualized using a UV lamp or permanganate stain. Column chromatography was performed using Silicycle Siliacflash G60 silica (60-200 μm). Chromatography eluents are reported as volume percent. Dialysis was performed using regenerated cellulose dialysis tubing obtained from Spectrum Labs. NMR spectra were
25 recorded on either a Bruker AV400 or AV300 instrument with chemical shifts reported relative to solvent signal. Abbreviations of splitting pattern designations are listed in the abbreviation section. ESI-MS was performed using a Waters LCT Premier spectrometer. Small molecule samples were prepared in MeOH (1 mg/mL) and injected at a rate of 20 μL/min. Peptide samples (5 mM) were analyzed analogously using a 50% MeCN/H₂O matrix.

30 *Abbreviations:* *N*-carboxyanhydride (NCA), degree of polymerization (DP), L-methionine (Met), poly(L-methionine) (**M**), *N,N,N',N',N''*-pentamethyldiethylenetriamine (PMDTA), potassium *tert*-butoxide (KO*t*Bu), glacial acetic acid (AcOH), 2,6-bis(1,1-dimethylethyl)-4-

methylphenol (BHT), ethanol (EtOH), ethyl acetate (EtOAc), diethyl ether (Et₂O), tetrahydrofuran (THF), trifluoroacetic acid (TFA), *meta*-chloroperbenzoic acid (mCPBA), hexafluoroisopropanol (HFIP), ethylene oxide (EO), molecular weight cut-off (MWCO), room temperature (RT), equivalents (eq), methanol (MeOH), liquid dinitrogen (LN₂), *N,N*-dimethylformamide (DMF),
 5 broad (br), doublet (d), doublet of doublets (dd), doublet of doublet of doublets (ddd), doublet of multiplets (dm), doublet of quartets (dq), doublet of triplets (dt), quartet (q), septet (sep), singlet (s), triplet (t), thin layer chromatography (TLC), electrospray ionization-mass spectrometry (ESI-MS)

General Synthetic Procedures



10 Poly(L-methionine)₆₀, M₆₀

Prepared by previously reported method. Kramer, J. R.; Deming, T. J. *Biomacromolecules* **2012**, 13, 1719-1723. Met NCA was polymerized with Co(PMe₃)₄ using a 20:1, monomer to initiator ratio. The DP was determined by endcapping a small aliquot from the polymerization mixture with 2 kDa PEG-isocyanate (CH₃(OCH₂CH₂)₄₅N=C=O) followed by ¹H NMR analysis.

15 Found Composition, DP = 59.

M₆₀ alkylation procedure A (Procedure A)

M₆₀ was suspended in glacial AcOH (16 mg/mL). The epoxide (3 eq per Met residue) was added in one portion. The mixture was stirred vigorously at 37° C. After 24 h, the limpid solution
 20 was transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM HCl_(aq) (24 h, 3 H₂O changes). The retentate was lyophilized, to provide the functionalized polypeptide.

M₆₀ alkylation procedure B (Procedure B)

M₆₀ was suspended in glacial AcOH (27 mg/mL). The epoxide (1.5 eq per Met residue)
 25 was added. The mixture was stirred vigorously at 37° C. After the peptide dissolved (*ca.* 2-6 h), a second portion of epoxide (1.5 eq per Met residue) was added. After 24 h, the limpid solution was transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM HCl_(aq) (24 h, 3 H₂O changes). The retentate was lyophilized, to provide the functionalized polypeptide.

M₆₀ glycosylation (Procedure C)

The procedure was analogous to *Procedure B*, however before transfer to the dialysis bag, 1 mL of 2 M HCl_(aq) was added. The solution was allowed to stand at RT for 16 h. After dialysis and lyophilization, the deprotected, fully glycosylated peptide was recovered.

5

Alternative M₆₀ alkylation using 1.5 eq of epoxide 4a

M₆₀ (6.0 mg) was suspended in glacial AcOH (0.20 mL). **4a** (3.4 mg, 0.034 mmol, 0.75 eq per Met residue) was added. The suspension was stirred vigorously at RT and became homogenous over 24 h. Another addition of **4a** (3.4 mg, 0.034 mmol, 0.75 eq per Met residue) was performed and stirring was continued for an additional 24 h. The reaction mixture was transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM HCl_(aq) (24 h, 3 H₂O changes). The retentate was lyophilized, to provide **4** (12 mg, 94% yield, >99% functionalized (¹H NMR)).

10

Alternative M₆₀ alkylation in aqueous buffer using epoxide 4a

M₆₀ (8.0 mg), was suspended in H₂O (0.50 mL) with vigorous stirring at RT. NaH₂PO₄•H₂O (17 mg, 0.12 mmol) and Na₂HPO₄•7H₂O (16 mg, 0.061 mmol) were added, followed by **4a** (18 mg, 0.18 mmol, 3 eq per Met residue). The mixture became completely limpid at 2 d and was stirred 3 d in total. The reaction mixture was transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM HCl_(aq) (24 h, 3 H₂O changes). The retentate was lyophilized, to provide a partially functionalized material (14 mg, 77% functionalized (¹H NMR)).

15


20

Poly(S-alkyl-L-methionine) stability studies


Polymer stock solutions (25 mmol Met residue per mL) were prepared in H₂O. Buffers were prepared by titrating 0.1 M solutions of the parent acid with 1 N NaOH. PBS 10x was prepared by dissolving a PBS tablet and adjusted to pH 7.4. The polymer stock (0.9 mL) was diluted with the buffer stock (0.1 mL) and if necessary, nucleophile (0.1 mmol) was added. The mixture was incubated on a 37° C H₂O bath for 24 h. The solution was transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM HCl_(aq) (24 h, 3 H₂O changes). The retentate was lyophilized. The products were analyzed by ¹H NMR, and the ratio of S-alkyl-Met/Met was determined. In all studies of **4**, **8** and poly(S-methylmethionine sulfonium chloride), mass recoveries were greater than 90%.

25


30

Example 1 – Synthesis of sulfonium polymers*Poly(S-(2-hydroxyethyl)-L-methionine sulfonium chloride), 1*


Prepared from **M₆₀** and **1a** using *Procedure A*. The reaction was conducted in a sealed glass ampule. ¹H NMR (300 MHz, D₂O, 25 °C): δ 4.70-4.53 (br m, 1H), 4.22-4.00 (br m, 2H), 3.81-3.41 (br m, 4H), 3.05 (d, *J* = 3.1 Hz, 3H), 2.58-2.20 (br m, 2H).

*Poly(S-(2-hydroxypropyl)-L-methionine sulfonium chloride), 2*

Prepared from **M₆₀** and **2a** using *Procedure A*. The product contained 6% (¹H NMR) of the 1-hydroxypropan-2-yl regioisomer. ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.72-4.53 (br m, 1H), 4.48-4.29 (br m, 1H), 3.81-3.39 (br m, 4H), 3.24-2.91 (br m, 3H), 2.62-2.23 (br m, 2H), 1.68-1.33 (m, 3H).

*Poly(S-(3-chloro-2-hydroxypropyl)-L-methionine sulfonium chloride), 3*


Prepared from **M₆₀** and **3a** using *Procedure A*. ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.71-4.59 (br m, 1H), 4.59-4.44 (br m, 1H), 3.94-3.42 (br m, 6H), 3.20-3.00 (br m, 3H), 2.59-2.26 (br m, 2H).



Poly(*S*-(3-azido-2-hydroxypropyl)-L-methionine sulfonium chloride), 4

Prepared from **M₆₀** and **4a** using *Procedure A*. ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.71-4.60 (br m, 1H), 4.51-4.37 (br m, 1H), 3.82-3.41 (br m, 6H), 3.21-3.00 (br m, 3H), 2.58-2.24 (br m, 2H).


5



Poly(*S*-(2-hydroxy-3-(2,2,2-trifluoroacetamido)propyl)-L-methionine sulfonium chloride), 5

Prepared from **M₆₀** and **5a** using *Procedure A*. ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.71-4.48 (br m, 1H), 4.48-4.27 (br m, 1H), 3.96-3.33 (br m, 6H), 3.30-2.90 (br m, 3H), 2.81-2.72 (br m, 1H), 2.59-2.27 (br m, 2H). ¹⁹F NMR (376 MHz, D₂O, 25 °C): δ -72.92.


10



Poly(*S*-(3-(allyloxy)-2-hydroxypropyl)-L-methionine sulfonium chloride), 6

Prepared from **M₆₀** and **6a** using *Procedure A*. ¹H NMR (400 MHz, D₂O, 25 °C): δ 6.07-5.90 (br m, 1H), 5.44-5.34 (br m, 1H), 5.34-5.26 (br m, 1H), 4.67-4.58 (br m, 1H), 4.47-4.32 (br m, 1H), 4.23-4.08 (br m, 2H), 3.81-3.40 (br m, 6H), 3.16-2.99 (br m, 3H), 2.56-2.23 (br m, 2H).


15



Poly(*S*-(2-hydroxy-3-(prop-2-yn-1-yloxy)propyl)-L-methionine sulfonium chloride), 7


Prepared from **M₆₀** and **7a** using *Procedure A*. ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.70-4.56 (br m, 1H), 4.52-4.38 (br m, 1H), 4.33 (s, 2H), 3.89-3.41 (br m, 6H), 3.23-3.04 (br m, 3H), 3.01 (s, 1H), 2.56-2.24 (br m, 2H).

20




Poly(*S*-(2-hydroxy-4,7,10,13-tetraoxatetradecyl)-L-methionine sulfonium chloride), 8

Prepared from **M₆₀** and **8a** using *Procedure A*, alkylation was allowed to proceed 36 h. ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.74-4.56 (br m, 1H), 4.53-4.32 (br m, 1H), 3.97-3.36 (br m, 21H), 3.31-2.97 (br m, 3H), 2.66-2.16 (br m, 2H).




Poly(*S*-(3-(diisopropoxyphosphoryl)-2-hydroxypropyl)-L-methionine sulfonium chloride), 9

Prepared from **M₆₀** and **9a** using *Procedure A*. The product was found to be 74% functionalized (¹H NMR). ¹H NMR (300 MHz, D₂O, 25 °C): δ 4.68-4.42 (br m, 2H), 3.87-3.38 (br m, 4H), 3.19-3.00 (br m, 3H), 2.72-2.54 (br m, 1.1H), 2.53-2.21 (br m, 4H), 2.20-2.00 (br m, 2.6H), 1.53-1.25 (d, *J* = 4.2 Hz, 12H). *Note*: Peaks arising from unfunctionalized Met residues are italicized.




Poly(*S*-(3-((2-bromo-2-methylpropanoyl)oxy)-2-hydroxypropyl)-L-methionine sulfonium chloride), 10

Prepared from **M₆₀** and **10a** using *Procedure A*. The product was found to be 52% functionalized (¹H NMR). ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.68-4.50 (br m, 1H), 4.50-4.31 (br m, 1H), 3.87-3.40 (br m, 4H), 3.30-3.03 (br m, 3H), 2.82-2.56 (br m, 2.4H), 2.57-2.27 (br m, 2H), 2.27-2.07 (br m, 4.9H), 2.07-1.89 (s, 6H). *Note*: Peaks arising from unfunctionalized Met residues are italicized.




Poly(*S*-((3-(1,2:5,6-Di-*O*-isopropylidene-3-deoxy- α -D-glucofuranosid-3-yl)oxy)-2-hydroxypropyl)-L-methionine sulfonium chloride), 11

Prepared from **M₆₀** and **12a** using *Procedure A*. The product was found to be 54% functionalized (¹H NMR). ¹H NMR (400 MHz, D₂O, 25 °C): δ 6.17-5.97 (br m, 1H), 5.02-4.87 (br m, 1H), 4.67-3.41 (br m, 13H), 3.23-2.94 (br m, 3H), 2.81-2.55 (br m, 1.8H), 2.56-2.26 (br m, 2H), 2.26-1.93 (br m, 4.3H), 1.74-1.28 (br m, 12H). *Note*: Peaks arising from unfunctionalized Met residues are italicized.




Poly(*S*-3-(3-(dimethoxyphosphoryl)propoxy)-2-hydroxypropyl)-L-methionine sulfonium chloride), 12

Prepared from **M₆₀** and **12a** using *Procedure B*. ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.72-4.53 (br m, 1H), 4.48-4.31 (br m, 1H), 3.96-3.75 (d, J = 10.9 Hz, 6H), 3.75-3.36 (br m, 8H), 3.21-2.96 (br m, 3H), 2.59-2.21 (br m, 2H), 2.10-1.96 (br m, 2H), 1.96-1.80 (br m, 2H).




Poly(*S*-3-(2-(1,3-diethoxy-1,3-dioxopropan-2-yl)ethoxy)-2-hydroxypropyl)-L-methionine sulfonium chloride), 13

Prepared from **M₆₀** and **13a** using *Procedure B*. ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.69-4.53 (br m, 1H), 4.45-4.32 (br m, 1H), 4.32-4.18 (br m, 4H), 3.84-3.38 (br m, 9H), 3.21-2.98 (br m, 3H), 2.58-2.27 (br m, 2H), 2.27-2.14 (br m, 2H), 1.42-1.18 (t, J = 7.1 Hz, 6H).



Poly(*S*-(2-hydroxy-3-((2-(2-bromo-2-methylpropanoyl)oxy)ethoxy)propyl)-L-methionine sulfonium chloride), 14


Prepared from **M₆₀** and **14a** using *Procedure B*. ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.71-4.59 (br m, 1H), 4.50-4.35 (br m, 3H), 3.98-3.83 (br m, 2H), 3.82-3.41 (br m, 6H), 3.19-3.01 (br m, 3H), 2.58-2.25 (br m, 2H), 2.10-1.89 (br m, 6H).



Poly(*S*-(2-hydroxy-3-(2-(isobutoxysulfonyl)ethoxy)propyl)-L-methionine sulfonium chloride),


15

Prepared from **M₆₀** and **15a** using *Procedure B*. Recovered product was found to be 11% deprotected (¹H NMR). ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.72-4.58 (br m, 1 H), 4.46-4.34 (br m, 1 H), 4.19 (d, *J* = 6.3 Hz, 2 H), 4.07 (m, 2 H), 3.82-3.41 (br m, 8 H), 3.15-2.98 (br m, 3 H), 2.51-2.25 (br m, 2 H), 2.08 (sep, *J* = 7.2 Hz, 1 H), 1.01 (d, *J* = 7.0 Hz, 6 H).



Poly(*S*-((3-(2-(3-deoxy-D-glucopyranosid-3-yl)oxy)ethoxy)-2-hydroxypropyl)-L-methionine sulfonium chloride), 16


Prepared from **M₆₀** and **16a** using *Procedure C*. The product was found to contain a 3:7 ratio of α:β anomers (¹H NMR) in D₂O at 25 °C. ¹H NMR (400 MHz, D₂O, 25 °C): δ 5.30-5.19 (br m, 0.3H), 4.72-4.52 (br m, 1.7H), 4.50-4.32 (br m, 1H), 4.12-3.96 (br m, 2H), 3.96-3.26 (br m, 14H), 3.23-2.94 (br m, 3H), 2.59-2.22 (br m, 1H).



Poly(*S*-((3-(2-(6-deoxy-D-galactopyranosid-6-yl)oxy)ethoxy)-2-hydroxypropyl)-L-methionine sulfonium chloride), 17

Prepared from **M₆₀** and **17a** using *Procedure C*. The product was found to contain a 3:7 ratio of α : β anomers (^1H NMR) in D_2O at RT. ^1H NMR (400 MHz, D_2O , 25 °C): δ 5.31-5.26 (d, J = 5.6 Hz, 0.3H), 4.70-4.56 (br m, 1.7H), 4.49-4.32 (br m, 1H), 4.10-3.39 (br m, 16H), 3.20-2.97 (br m, 3H), 2.56-2.23 (br m, 2H).

Example 2 – Deprotection of functional sulfonium polypeptides




Poly(*S*-(3-ammonio-2-hydroxypropyl)-L-methionine sulfonium dichloride)

A solution of **5** (18 mg, 0.048 mmol) in H_2O (1.5 mL) was treated with K_2CO_3 (10 mg, 0.072 mmol). The solution was allowed to stand 24 h. The solution was transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM $\text{HCl}_{(\text{aq})}$ (24 h, 3 H_2O changes). The retentate was lyophilized, to provide the deprotected polypeptide (14 mg, 93% yield) which was found to be fully deprotected (^{19}F NMR).

Alternate Method: A solution of **5** (8.0 mg, 0.023 mmol) in absolute EtOH (0.5 mL) was stirred at RT. NaBH_4 (5.0 mg, 0.125 mmol) was added and the solution was stirred vigorously for 30 min. Another portion of NaBH_4 (5.0 mg, 0.125 mmol) was added and the suspension was allowed to stir an additional 30 min. The suspension was acidified with dilute $\text{HCl}_{(\text{aq})}$ and transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM $\text{HCl}_{(\text{aq})}$ (24 h, 3 H_2O changes). The retentate was lyophilized, to provide the deprotected polypeptide (6.9 mg, 95% yield) which was found to be fully deprotected (^{19}F NMR).

^1H NMR (400 MHz, D_2O , 25 °C): δ 4.712-4.45 (br m, 2 H), 3.90-3.46 (br m, 4 H), 3.41-3.04 (br m, 5 H), 2.60-2.25 (br m, 2 H). ^{19}F NMR (376 MHz, D_2O , 25 °C): No Peaks.




Poly(*S*-(3-(2-(1-Hydroxy-3-oxido-1,3-dioxopropan-2-yl)ethoxy)-2-hydroxypropyl)-L-methionine sulfonium)

5 A solution of **13** (8.9 mg, 0.021 mmol) in H₂O (0.4 mL), was treated with 1 N NaOH_(aq) (0.15 mL, 0.15 mmol). The solution was allowed to stand 16 h at 4 °C. The solution was acidified with dilute HCl_(aq), transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM HCl_(aq) (24 h, 3 H₂O changes). The retentate was lyophilized to provide the deprotected polypeptide (6.7 mg, 96 % yield) which was found to be >99% deprotected (¹H NMR).

10 *Alternate Method:* The deprotection was conducted as above, with 1 N NaOH_(aq) (0.10 mL, 0.10 mmol) at RT for 4 h. The polypeptide (6.7 mg, 96 % yield) was found to be >97% deprotected (¹H NMR).

¹H NMR (400 MHz, D₂O, 25 °C): 4.69-4.50 (br m, 1 H), 4.50-4.43 (br m, 1 H), 3.82-3.34 (br m 8 H), 3.06 (m, 3 H), 2.60-2.06 (br m, 4 H).

15




Poly(*S*-(2-hydroxy-3-(2-(oxidosulfonyl)ethoxy)propyl)-L-methionine sulfonium chloride)

20 A solution of **15** (8.0 mg, 0.020 mmol) was dissolved in 10% (w/v) NaN_{3(aq)} (0.5 mL). The solution was stirred for 24 h on a 37 °C H₂O bath. The solution was transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM HCl_(aq) (24 h, 3 H₂O changes). The retentate was lyophilized, to provide the deprotected polypeptide (5.7 mg, 91% yield) which was found to be >99% deprotected (¹H NMR). ¹H NMR (400 MHz, D₂O, 25 °C): δ 4.67-4.55 (br m, 1 H), 4.47-4.34 (br m, 1 H), 4.03 (m, 2 H), 3.81-3.38 (br m, 6 H), 3.24 (t, *J* = 5.7 Hz, 2 H), 3.04 (m, 3 H), 2.54-2.23 (br m, 2 H).

Note: Deprotection under the same conditions with 10% NaI provided a 77% deprotected material. Using 0.67 M HBr: 60% deprotection. In all cases no side products due to sulfonium decomposition were observed.


5 *Example 3 – Further functionalization of functional sulfonium polypeptides*



Poly(*S*-(2-hydroxy-3-(4-(2,5,8,11-tetraoxadodecyl)-1*H*-1,2,3-triazol-1-yl)propyl)-*L*-methionine sulfonium chloride


A solution of **4** (15 mg, 0.056 mmol azide), 2,5,8,11-tetraoxatetradec-13-yne (21 mg, 0.10 mmol) and sodium ascorbate (5.0 mg, 0.025 mmol) was degassed in H₂O (0.50 mL) by stirring under N₂ for 1 hr. A separate solution of PMDTA (2.0 μL, 0.010 mmol) and CuSO₄•5H₂O (1.3 mg, 0.0051 mmol) in H₂O (0.50 mL) was degassed analogously. The copper solution was added to the azide solution and stirring of the mixture was continued for 24 h. The solution was transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM HCl_(aq) (36 h, 5 H₂O changes). The retentate was filtered through a 0.45 μM syringe filter and lyophilized, to provide the completely PEGylated polypeptide (19 mg, 89% yield). ¹H NMR (400 MHz, D₂O, 25 °C): δ 8.27-7.95 (br s, 1 H), 4.75-4.56 (br m, 4 H), 3.83-3.54 (br m, 18 H), 3.38 (s, 3 H), 3.13-3.00 (br m, 3 H), 2.55-2.23 (br m, 2 H).

20 *Example 4 - Chemoselectivity of Met alkylations*




Poly[(*L*-methionine)_{0.2}-*stat*-(*L*-lysine hydrochloride)_{0.8}]₈₀, (M_{0.2}K_{0.8})₈₀

Prepared by previously reported method. Kramer, J. R.; Deming, T. J. *Biomacromolecules* **2012**, *13*, 1719-1723. Briefly, ϵ -TFA-lysine NCA and Met NCA were polymerized with $\text{Co}(\text{PMe}_3)_4$ using a 30:1, monomer to initiator ratio. The polymer was deprotected using $\text{K}_2\text{CO}_3/\text{MeOH}$ followed by dialysis and cation exchange. DP was determined by endcapping a small aliquot from the polymerization mixture with 2 kDa PEG-isocyanate ($\text{CH}_3(\text{OCH}_2\text{CH}_2)_{45}\text{N}=\text{C}=\text{O}$) followed by ^1H NMR analysis. Found composition: $(\text{M}_{0.2}\text{K}_{0.8})_{82}$.



Poly[(*S*-(3-azido-2-hydroxypropyl)- L-methionine sulfonium chloride)_{0.2}-*stat*-(L-lysine hydrochloride)_{0.8}]₈₀

A suspension of $(\text{M}_{0.2}\text{K}_{0.8})_{80}$ (6 mg) in a mixture of 0.1 M NaOAc/AcOH (0.17 mL) and HFIP (0.030 mL) was treated with **4a** (1.5 μL , 2 eq per Met residue). The mixture was stirred vigorously for 16 h at RT. The mixture was treated again with **4a** (1.5 μL , 2 eq per Met residue) and stirring was continued for another 24 h. The reaction mixture was transferred to a 2 kDa MWCO dialysis bag and dialyzed against 3 mM $\text{HCl}_{(\text{aq})}$ (24 h, 3 H_2O changes). The retentate was lyophilized, to provide **21** (6.2 mg, 88% yield). ^1H NMR (400 MHz, D_2O , 25 $^\circ\text{C}$): δ 4.68-4.57 (br m, 0.2 H), 4.52-4.16 (br m, 1.2 H), 3.88-3.35 (br m, 1.2 H), 3.08 (m, 2.6 H), 2.49-2.20 (br m, 0.4 H), 2.16-1.24 (br m, 6 H).



PHCKRM-Glycidyl Azide Conjugate, 18

A solution of peptide **PHCKRM** (2.0 mg, 0.0026 mmol) in glacial AcOH (0.30 mL) was treated with **4a** (2.6 mg, 0.026 mmol). The solution was stirred for 48 h. The mixture was concentrated under high vacuum and the residue was triturated with 3x 0.5mL Et₂O; the solids were separated by centrifugation after each step. Residual ether was evaporated under high vacuum and completely removed by re-dissolving the solid in H₂O (0.5 mL) and lyophilizing the solution. Colorless solid (1.7 mg). ESI-MS $m/z = 870.1824 M^+$ (calcd 870.4191 for C₃₄H₆₀N₁₅O₈S₂).


Example 5 - Preparation of epoxides

Epoxidation Procedure (Procedure D)

The alkene (1 eq) was dissolved in CH₂Cl₂ (3.3 mL/mmol alkene). Commercial 70% mCPBA (1.5 eq) was added and the mixture was stirred at room temperature. After TLC showed full conversion of the alkene (36-48 h) the suspension was cooled on an ice bath. The mixture was treated with 10% Na₂SO_{3(aq)} (1.5 eq) followed by 10% Na₂CO_{3(aq)} (1.3 eq) and stirred for 5 min. The reaction mixture was diluted with EtOAc, and washed 2x with sat. NaHCO_{3(aq)} followed by brine. The organic extract were dried over Na₂SO₄, concentrated *in vacuo* and purified by flash chromatography.

'Dry' Epoxidation Procedure (Procedure E)

A stock solution of 0.45 M mCPBA in CH₂Cl₂ was prepared from commercial 70% mCPBA. This solution was dried over MgSO₄ and freed of drying agent by centrifugation. The alkene (1 eq) was treated with this 'dry' mCPBA solution (1.5 eq). Thereafter, the synthesis was conducted analogous to *Procedure D*.




Glycidyl azide, 4a

Epichlorohydrin (4.0 mL, 51 mmol) was added to a solution of sodium azide (4.0 g, 61 mmol) and acetic acid (3.5 mL, 61 mmol) in 25% (v/v) ethanol/water (20 mL). The biphasic mixture was stirred vigorously at room temperature for 24 h. Brine (25 mL) was added and the mixture was extracted with EtOAc (3x 40 mL). The combined extracts were dried over Na₂SO₄ and concentrated *in vacuo* to provide *1-azido-3-chloropropan-2-ol* as a colorless oil (6.7 g, 97%


yield). ^1H NMR (400 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ 3.99 (pent, $J = 5.5$ Hz, 1 H), 3.66-3.56 (m, 2 H), 3.48 (d, $J = 5.3$ Hz, 2 H).

An aqueous solution of 1 N sodium hydroxide (55 mL, 55 mmol) was added to 1-azido-3-chloropropan-2-ol with stirring on a RT H_2O bath. Stirring was continued for 30 min after the addition. The suspension was then extracted with CH_2Cl_2 (3x30 mL). The combined extracts were washed with brine (20 mL) and dried over Na_2SO_4 . Concentration *in vacuo* provided **4a** (4.0 g, 83% yield) as a colorless mobile oil. ^1H NMR (400 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ 3.56 (dd, $J = 13.8$, 3.2 Hz, 1 H), 3.31 (dd, $J = 13.5$, 5.4 Hz, 1 H), 3.19 (m, 1 H), 2.84 (dd, $J = 4.7$, 4.1 Hz, 1 H), 2.71 (dd, $J = 4.8$, 2.5 Hz, 1 H).



2,2,2-trifluoro-N-(oxiran-2-ylmethyl)acetamide, **5a**

Prepared from N-allyl-2,2,2-trifluoroacetamide by *Procedure D*. Flash chromatography eluent: 30% EtOAc/Hexanes. Colorless mobile oil, 74% yield. R_F : 0.33; 30% EtOAc/Hexanes. ^1H NMR (300 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ 7.35-6.99 (br s, 1H), 3.82 (ddd, $J = 14.7$, 6.3, 3.0 Hz, 1 H), 3.34 (dt, $J = 14.6$, 5.7 Hz, 1 H), 3.14 (m, 1 H), 2.82 (t, $J = 4.3$ Hz, 1 H), 2.60 (dd, $J = 4.5$, 2.8 Hz, 1 H). ^{13}C NMR (100 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ 158.4 (q, $J = 37.8$ Hz), 120.2 (q, $J = 287.4$ Hz), 49.8, 45.3, 41.4. ^{19}F NMR (376 MHz, D_2O , 25 $^\circ\text{C}$): δ -76.0.



2-(2,5,8,11-tetraoxadodecyl)oxirane, **8a**


A stirred solution of triethylene glycol monomethyl ether (10 g, 61 mmol) and water (1.0 mL) on an ice bath was treated with NaOH (7.2 g, 180 mmol) followed by 0.4 M tetrabutylammonium hydroxide_(aq) (7.7 mL, 3.1 mmol). Once the mixture returned to 0 $^\circ\text{C}$, epichlorohydrin (14 mL, 180 mmol) was added portionwise over 3 min. The mixture was stirred at room temperature 16 h. H_2O (15 mL) was added and the mixture was extracted with EtOAc (4x 30 mL). The combined extracts were washed with brine (30 mL) and dried over Na_2SO_4 . The extracts were concentrated by rotary evaporation. The residue was distilled *in vacuo*, providing **8a** (11 g, 79% yield) as a colorless liquid boiling at 110-117 $^\circ\text{C}$ (0.1 mmHg). ^1H NMR (400 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ 3.80 (dd, $J = 15.5$, 4.1, 1 H), 3.71-3.62 (m, 10 H), 3.54 (m, 2 H), 3.44 (dd, $J = 15.5$, 7.8

Hz, 1 H), 3.37 (s, 3 H), 3.15 (m, 1 H), 2.79 (dd, $J = 6.6, 5.6$ Hz, 1 H), 2.61 (dd, $J = 6.7, 3.6$ Hz, 1 H).




5 Diisopropyl allylphosphonate, **9b**

Allyl bromide (1.8 mL, 20 mmol) was added to a mixture of BHT (10 mg) in triisopropyl phosphite (5 mL, 20 mmol). The flask was set-up for reflux and heated on a 115 °C oil bath for 16 h. The reaction mixture was vacuum distilled to provide **9b** (4.2 g, 100% yield) as a colorless oil boiling at 40-41° C (0.1 mmHg). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ 5.83-5.75 (m, 1 H), 5.18 (m, 2 H), 4.72-4.64 (m, 2 H), 2.58 (dd, $J = 21.9, 7.4$ Hz, 2 H), 1.30 (dd, $J = 6.2, 4.6$ Hz, 12 H).




Diisopropyl (oxiran-2-ylmethyl)phosphonate, **9a**

Prepared from **9b** by *Procedure D*. Flash chromatography eluent, 75% EtOAc/Hexanes to neat EtOAc. Colorless oil. Yield 75%. R_F : 0.2; 75% EtOAc/Hexanes. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ 4.74 (m, 2 H), 3.17 (m, 1 H), 2.84 (t, $J = 4.8$ Hz, 1 H), 2.59 (dd, $J = 4.8, 2.6$ Hz, 1 H), 2.22 (m, 1 H), 1.77 (ddd, $J = 21.9, 15.0, 6.7$ Hz, 1 H), 1.34 (d, $J = 6.4$ Hz, 12 H).




20 Glycidyl 2-bromo-2-methylpropanoate, **10a**

Prepared by previously reported procedure. Gadwal, I.; Khan A. *Polym. Chem.* **2013**, 4, 2440-2444.




25 2-((1,2:5,6-Di-O-isopropylidene-3-deoxy-α-D-glucofuranosid-3-yl)oxymethyl)oxirane, **11a**

Prepared by previously reported procedure. Khan, A.R.; Tripathi, R.P.; Bhaduri, A.p.; Sahai, R.; Puri, A.; Tripathi, L.M.; Srivastava, V.M.L. *Eur. J. Med. Chem.* **2001**, 36, 435-445.




5 2-(3-(dimethoxyphosphoryl)propoxymethyl)oxirane, 12a

Prepared by previously reported procedure. Brel, A.K.; Petrov, V.I.; Ozerov, A.A.; Gunger, A.A.; Sazhin, V.A. *Pharm Chem J.* **1992**, 26, 772-774.



10 2-allyloxyethyl methanesulfonate


Prepared by previously reported procedure. Bala K.; Hailes H.C. *Synthesis* **2005**, 2005, 3423-3427. Colorless to pale yellow oil, stable at room temp when stored in amber glass bottle.



15 2-(2-(1,3-diethoxy-1,3-dioxopropan-2-yl)ethoxymethyl)oxirane, 13a


A suspension of 60% NaH (1.44 g, 36 mmol) and KI (5.4 g, 1 eq) in DMF (125 mL) was stirred on an ice bath. Diethyl malonate (5.0 mL, 33 mmol) was added dropwise and allowed to stir for 5 min. 2-Allyloxyethyl methanesulfonate (8.8 g, 49 mmol) was added portionwise. The mixture was stirred at 60 °C for 18 h. The solvent was evaporated *in vacuo* and the residue was diluted with 200 mL EtOAc. The solution was washed with 250 mL H₂O. The aqueous wash was extracted with 2x 125 mL EtOAc. The combined organic extracts were dried over Na₂SO₄ and concentrated by rotary evaporation. The residue was purified by filtering through a silica plug with 10% EtOAc/Hexanes. After concentration, 7.3 g of a colorless oil was recovered. The oil was found by ¹H NMR to contain diethyl 2-(2-(allyloxy)ethyl)malonate (79% yield) with 12 mol % diethyl 2,2-bis(2-(allyloxy)ethyl)malonate. From this mixture **13a** was prepared by *Procedure D*. Flash chromatography eluent: 25% EtOAc/Hexanes. The title compound, **13a** (6.5 g, 76% yield overall) was recovered as a colorless oil. *R_F* = 0.39; 30% EtOAc/Hexanes. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ 4.19 (q, *J* = 7.0 Hz, 4 H), 3.70 (dd, *J* = 11.8, 3.0 Hz, 1 H), 3.53 (m, 3 H), 3.35 (dd, *J* = 11.8, 5.6 Hz, 1 H), 3.10 (m, 1 H), 2.77 (t, *J* = 4.5 Hz, 1H), 2.58 (dd, *J* = 5.0, 2.5 Hz, 1H), 2.18 (q, *J* = 6.3

Hz, 2 H), 1.26 (t, $J = 7.2$ Hz, 6 H). ^{13}C NMR (100 MHz, CDCl_3 , 25 °C): δ 169.2, 71.3, 68.5, 61.3, 50.6, 48.9, 44.0, 28.7, 13.9. ESI-MS $m/z = 283.2110$ $[\text{M} + \text{Na}]^+$ (calcd 283.1158 for $\text{C}_{12}\text{H}_{20}\text{NaO}_6$).



5 2-(allyloxy)ethyl 2-bromo-2-methylpropanoate, 14b


A solution of 2-allyloxyethanol (1.0 mL, 9.3 mmol) and pyridine (2.3 mL, 28 mmol) in CH_2Cl_2 (75 mL) was stirred on a -10 °C MeOH bath. 2-Bromoisobutyryl bromide (2.3 mL, 19 mmol) was added dropwise. The solution was removed from the bath and stirred at room temperature for 3.5 h. Water (0.3 mL) was added and the solution was concentrated *in vacuo*. The residue was purified by flash chromatography, 15% EtOAc/Hexanes. **12a** was recovered as a colorless oil (2.2 g, 99%). $R_F = 0.50$; 15% EtOAc/Hexanes. ^1H NMR (400 MHz, CDCl_3 , 25 °C): δ 5.87 (m, 1 H), 5.31 (dm, $J = 17.3$ Hz, 1 H), 5.20 (dm, $J = 10.5$ Hz, 1 H), 4.33 (t, $J = 5.0$ Hz, 2 H), 4.03 (dt, $J = 5.6$, 1.5 Hz, 2H), 3.69 (t, $J = 5.0$ Hz, 2H), 1.94 (s, 6 H). ^{13}C NMR (100 MHz, CDCl_3 , 25 °C): δ 171.6, 134.3, 117.2, 72.0, 67.4, 65.0, 55.6, 30.7. ESI-MS $m/z = 273.2030$ $[\text{M} + \text{Na}]^+$ (calcd 273.0102 for $\text{C}_9\text{H}_{15}\text{BrO}_3\text{Na}$).



2-(2-((2-bromo-2-methylpropanoyl)oxy)ethanoxymethyl)oxirane, 14a

Prepared from **14b** by *Procedure D*. Flash chromatography eluent: 30% EtOAc/Hexanes. Recovered as a colorless oil, 71% yield. $R_F = 0.34$; 30% EtOAc/Hexanes. ^1H NMR (400 MHz, CDCl_3 , 25 °C): δ 4.33 (t, $J = 5.1$ Hz, 2 H), 3.73 (m, 3 H), 3.46 (dd, $J = 11.7$, 5.7 Hz, 1 H), 3.16 (m, 1 H), 2.77 (dd, $J = 5.0$, 4.2 Hz, 1 H), 2.62 (dd, $J = 5.1$, 2.7 Hz), 1.94 (s, 6 H). ^{13}C NMR (100 MHz, CDCl_3 , 25 °C): δ 171.5, 71.7, 68.8, 64.9, 55.6, 50.7, 43.9, 30.7. ESI-MS $m/z = 289.00$ $[\text{M} + \text{Na}]^+$ (calcd 289.01 for $\text{C}_9\text{H}_{15}\text{BrO}_4\text{Na}$).


25



Isobutyl 2-(allyloxy)ethane-1-sulfonate, 15b

Isobutyl ethenesulfonate (0.50 mL, 3.6 mmol) was added to dry allyl alcohol (7.0 mL). The mixture was stirred on a MeOH bath maintained at ca. -20 °C by periodic additions of LN₂. KO^tBu (40 mg, 0.36 mmol) was added. The mixture was stirred overnight while the bath was allowed to warm to 10 °C. AcOH (6 μL, 0.4 mmol) was added and the mixture was concentrated *in vacuo*.

- 5 The residue was dissolved in EtOAc (50 mL) and washed with 0.01 N HCl_(aq) (40 mL) followed by H₂O (40 mL). The organic extract was dried over Na₂SO₄ and concentrated by rotary evaporation. The residue was purified by flash chromatography (15% EtOAc/Hexanes). Alkene **15b** (0.50 g, 62% yield) was recovered as a colorless oil. R_F = 0.30; 15% EtOAc/Hexanes. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ 5.89 (m, 1 H), 5.27 (dm, J = 17.2 Hz, 1 H), 5.21 (dm, J = 10.5 Hz, 1 H), 4.02 (dt, J = 5.6, 1.4 Hz, 2 H), 4.01 (d, J = 6.6 Hz, 2 H), 3.86 (t, J = 6.4 Hz, 2 H), 3.39 (t, J = 6.6 Hz, 2 H), 2.02 (sep, J = 6.6 Hz, 1 H), 0.98 (d, J = 6.6 Hz, 6 H). ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ 133.8, 117.9, 76.1, 72.3, 63.6, 50.4, 28.3, 18.7. ESI-MS m/z = 245.0810 [M + Na]⁺ (calcd 245.0823 for C₉H₁₈O₄SNa).




15

Isobutyl 2-(oxiran-2-ylmethoxy)ethane-1-sulfonate, **15a**

Prepared from **15b** by *Procedure D*. Flash chromatography eluent: 30% EtOAc/Hexanes. Recovered as a colorless oil, 78% yield. R_F = 0.32; 40% EtOAc/Hexanes. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ 4.00 (d, J = 6.6 Hz, 2 H), 3.91 (m, 2 H), 3.84 (dd, J = 11.6, 2.6 Hz, 1 H), 3.39 (d, J = 6.6 Hz, 2 H), 3.37 (d, J = 5.7 Hz, 1 H), 3.13 (m, 1 H), 2.78 (t, J = 4.4 Hz, 1 H), 2.60 (dd, J = 4.8, 2.4 Hz, 1 H), 2.01 (sep, J = 6.6 Hz, 1 H), 0.98 (d, J = 6.8 Hz, 6 H). ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ 76.1, 72.0, 64.9, 50.5, 50.3, 44.0, 28.3, 18.6. ESI-MS m/z = 245.0823 [M + Na]⁺ (calcd 261.0773 for C₉H₁₈O₅SNa).


20



25


3-(2-(allyloxy)ethoxy)1,2:5,6-di-*O*-isopropylidene-3-deoxy-α-D-glucufuranoside, **16b**

1,2:5,6-di-O-isopropylidene- α -D-glucofuranose (0.75 g, 2.9 mmol) and KI (0.46 g, 2.9 mmol) were dried under high vacuum for *ca.* 15 min. DMF (40 mL) was transferred by cannula into the reaction flask, and the mixture was cooled on an ice bath. 60% NaH (0.17g, 4.3 mmol) was added in one portion. After 5 min, the ice bath was removed and the mixture was allowed to stir 20 min at room temperature. 2-allyloxyethyl methanesulfonate (1.2 mL, 5.7 mmol) was added and the mixture was stirred 48 h on a 60°C oil bath. The reaction mixture was concentrated under high vacuum overnight. The residue was directly purified by flash chromatography (7.5% Acetone/Hexanes). Alkene **16b** (0.80 g, 81% yield) was recovered as a thick colorless oil. R_F = 0.24; 10% Acetone/Hexanes. ^1H NMR (400 MHz, CDCl_3 , 25 °C): δ 5.89 (m, 2 H), 5.29 (dm, J = 17.3 Hz, 1 H), 5.19 (dm, J = 10.9 Hz, 1 H), 4.59 (d, J = 4.1 Hz, 1 H), 4.32 (q, J = 6.12, 1 H), 4.12 (dd, J = 7.5, 3.0 Hz, 1 H), 4.08 (dd, J = 8.5, 6.1 Hz, 1 H), 4.00 (m, 3 H), 3.93 (d, J = 2.7 Hz, 1 H), 3.75 (m, 2 H), 3.56 (t, J = 4.8 Hz, 2 H), 1.49 (s, 3 H), 1.42 (s, 3 H), 1.34 (s, 3 H), 1.30 (s, 3 H). ^{13}C NMR (100 MHz, CDCl_3 , 25 °C): δ 134.6, 116.8, 111.6, 108.8, 105.2, 82.7, 82.6, 81.1, 72.5, 72.1, 70.2, 69.3, 67.1, 26.8, 26.7, 26.1, 25.3. ESI-MS m/z = 367.18 $[\text{M} + \text{Na}]^+$ (calcd 367.17 for $\text{C}_{17}\text{H}_{28}\text{O}_7\text{Na}$).



2-(2-((1,2:5,6-di-O-isopropylidene-3-deoxy- α -D-glucofuranosid-3-yl)oxy)ethoxymethyl)oxirane, 16a


Prepared from **16b** by *Procedure E*. Flash chromatography eluent: 20% Acetone/Hexanes. Colorless thick oil, 82 % yield. R_F = 0.30; 20% Acetone/Hexanes. ^1H NMR (400 MHz, CDCl_3 , 25 °C): δ 5.87 (d, J = 3.8 Hz, 1 H), 4.57 (d, J = 3.5 Hz, 1 H), 4.32 (q, J = 6.2 Hz, 1 H), 4.10 (m, 2 H), 3.99 (dd, J = 8.5, 5.8 Hz, 1 H), 3.93 (d, J = 2.8 Hz, 1 H), 3.80 (dd, J = 11.7, 2.8 Hz, 1 H), 3.77–3.63 (m, 4 H), 3.41 (ddd, J = 11.3, 5.8, 3.5 Hz, 1 H), 3.14 (m, 1 H), 2.78 (t, J = 4.6 Hz, 1 H), 2.60 (m, 1 H), 1.48 (s, 3 H), 1.41 (s, 3 H), 1.33 (s, 3 H), 1.31 (s, 3 H). ^{13}C NMR (100 MHz, CDCl_3 , 25 °C): δ 111.6, 108.8, 105.2, 82.7, 82.6, 81.0, 72.4, 71.8, 70.6, 70.0, 67.1, 50.7, 44.0, 26.8, 26.7, 26.1, 25.3. ESI-MS m/z = 383.1663 $[\text{M} + \text{Na}]^+$ (calcd 383.1682 for $\text{C}_{17}\text{H}_{28}\text{O}_8\text{Na}$).



6-(2-(allyloxy)ethoxy)-1,2:3,4-di-O-isopropylidene-6-deoxy- α -D-galactopyranoside, 17b

Prepared analogously to **16b** using 1,2:3,4-di-O-isopropylidene- α -D-galactopyranose as the substrate. Flash chromatography eluent: 7.5% Acetone/Hexanes. Colorless thick oil, 86 % yield. R_F

- 5 = 0.31; 10% Acetone/Hexanes. ^1H NMR (400 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ 5.94 (m, 1 H), 5.54 (d, J = 5.0 Hz, 1 H), 5.30 (dq, J = 16.9, 1.5 Hz, 1 H), 5.19 (dm, J = 10.7 Hz, 1 H), 4.61 (dd, J = 8.0, 2.4 Hz, 1 H), 4.31 (dd, J = 5.0, 2.4 Hz, 1 H), 4.28 (dd, J = 7.7, 2.1 Hz, 1 H), 4.03 (m, 3 H), 3.75-3.60 (m, 6 H), 1.53 (s, 3 H), 1.44 (s, 3 H), 1.34 (s, 3 H), 1.33 (s, 3 H). ^{13}C NMR (100 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ 134.8, 116.9, 109.1, 108.4, 96.3, 72.1, 71.1, 70.7, 70.6, 70.5, 69.8, 69.3, 66.7, 26.0, 25.9, 24.8, 24.3. ESI-MS m/z = 367.17 $[\text{M} + \text{Na}]^+$ (calcd 367.17 for $\text{C}_{17}\text{H}_{28}\text{O}_7\text{Na}$).
- 10



2-(2-((1,2:3,4-di-O-isopropylidene-6-deoxy- α -D-galactopyranosid-6-yl)oxy)ethoxymethyl)oxirane, 17a

- 15 Prepared from **17b** by *Procedure E*. Flash chromatography eluent: 15-20% Acetone/Hexanes. Colorless thick oil, 94 % yield. R_F = 0.19; 15% Acetone/Hexanes. ^1H NMR (400 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ 5.53 (d, J = 5.0 Hz, 1 H), 4.60 (dd, J = 8.1, 2.5 Hz, 1 H), 4.30 (dd, J = 4.9, 2.4 Hz, 1 H), 4.26 (dd, J = 7.9, 1.5 Hz, 1 H), 3.98 (t, J = 6.1 Hz, 1 H), 3.79 (dm, J = 11.7 Hz), 3.72-3.60 (m, 6 H), 3.47 (ddd, J = 11.6, 5.7, 3.3 Hz, 1 H), 3.15 (m, 1 H), 2.78 (t, J = 4.7 Hz, 1 H), 2.61 (m, 1 H), 1.53 (s, 3 H), 1.43 (s, 3 H), 1.33 (s, 3 H), 1.32 (s, 3 H). ^{13}C NMR (100 MHz, CDCl_3 , 25 $^\circ\text{C}$): δ 109.3, 108.6, 96.4, 72.0, 71.9, 71.2, 70.9, 70.7, 70.6, 70.0, 66.9, 50.9, 44.4, 26.2, 26.1, 25.0, 24.5. ESI-MS m/z = 383.1698 $[\text{M} + \text{Na}]^+$ (calcd 383.1682 for $\text{C}_{17}\text{H}_{28}\text{O}_8\text{Na}$).
- 20

Incorporation by Reference


- 25 All of the U.S. patents and U.S. patent application publications cited herein are hereby incorporated by reference.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.


What is claimed is:


1. A compound of Formula I:



Formula I

- 5 wherein, independently for each occurrence,
 - R^1 is H or alkyl;
 - R^2 is alkyl;
 - R^3 is H or substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted
 - 10 heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido;
 - m is 1-200, inclusive;
 - n is 1-4, inclusive;
 - 15 A^1 is H, an amine protecting group, a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein;
 - A^2 is OH, -O-(a carboxylate protecting group), a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein; and
 - X is a monovalent anion.
- 20
2. The compound of claim 1, wherein R^1 is H.
3. The compound of claim 1, wherein R^1 is alkyl.
- 25 4. The compound of claim 1, wherein R^1 is methyl or ethyl.
5. The compound of any of claims 1-4, wherein R^2 is methyl, ethyl, n-propyl, or n-butyl.

6. The compound of any of claims 1-4, wherein R^2 is methyl.
7. The compound of any of claims 1-6, wherein R^3 is substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido.
8. The compound of any of claims 1-6, wherein R^3 is unsubstituted amino, unsubstituted alkyl, unsubstituted alkyloxy, azido, unsubstituted aryl, unsubstituted heteroaryl, halo, unsubstituted allyloxy, unsubstituted alkylcarbonyloxy, unsubstituted phosphonate, unsubstituted carbamate, or unsubstituted amido.
9. The compound of any of claims 1-6, wherein R^3 is substituted amino, substituted alkyl, substituted alkyloxy, substituted aryl, substituted heteroaryl, substituted allyloxy, substituted alkylcarbonyloxy, substituted phosphonate, substituted carbamate, or substituted amido.
10. The compound of any of claims 1-6, wherein R^3 is substituted alkyloxy.
11. The compound of any of claims 1-6, wherein R^3 is heterocycloalkyloxy, phosphonate-substituted alkyloxy, acyloxyalkyloxy, aminoalkyloxy, aminoalkylamidoalkyloxy, or alkyloxycarbonylalkyloxy.
12. The compound of any of claims 1-6, wherein R^3 is -L-halo, -L-azide, -L-NHR¹, -L-NR¹-TFA, -L-NR¹-C(O)-O-alkyl, -L-NR¹-C(O)-CH₂-NR¹-TFA, -L-O-CH₂-CH=CH₂, -L-O-CH₂CCH, -L-O-alkyl, -L-O-C(O)-alkyl, -L-P(O)(O-alkyl)₂, -L-P(O)(OH)₂, -L-O-C(O)-C(halo)(alkyl)₂, -L-CH₂-P(O)(O-alkyl)₂, -L-CH₂-P(O)(OH)₂, -L-O-CH₂CH-(C(O)NR¹-alkyl)(NR¹-TFA), -L-O-CH₂CH-(C(O)OR¹)(NR¹-TFA), -L-OCH₂-C(O)-OR¹, -L-CH-(CO₂-alkyl)₂, -L-CH-(CO₂H)₂, -L-SO₂(O-alkyl), -L-SO₂(O-aryl), -L-SO₃H,
- 



L is a bond or $-(\text{OCH}_2\text{CH}_2)_x-$, and x is 1-10.

13. The compound of claim 12, wherein R^3 is -L-halo.

5

14. The compound of claim 12, wherein R^3 is -L-azide.

15. The compound of claim 12, wherein R^3 is -L-NHR¹.

10 16. The compound of claim 12, wherein R^3 is -L-NR¹-TFA.

17. The compound of claim 12, wherein R^3 is -L-NR¹-C(O)-O-alkyl.

18. The compound of claim 12, wherein R^3 is -L-NR¹-C(O)-CH₂-NR¹-TFA.

15

19. The compound of claim 12, wherein R^3 is -L-O-CH₂-CH=CH₂.

20. The compound of claim 12, wherein R^3 is -L-O-CH₂CCH.

20 21. The compound of claim 12, wherein R^3 is -L-O-alkyl.

22. The compound of claim 12, wherein R^3 is -L-O-C(O)-alkyl.

23. The compound of claim 12, wherein R^3 is -L-P(O)(O-alkyl)₂.


25


24. The compound of claim 12, wherein R^3 is -L-P(O)(OH)₂.

25. The compound of claim 12, wherein R^3 is -L-O-C(O)-C(halo)(alkyl)₂.


26. The compound of claim 12, wherein R^3 is $-L-CH_2-P(O)(O-alkyl)_2$.
27. The compound of claim 12, wherein R^3 is $-L-CH_2-P(O)(OH)_2$.
- 5 28. The compound of claim 12, wherein R^3 is $-L-O-CH_2CH-(C(O)NR^1-alkyl)(NR^1-TFA)$.
29. The compound of claim 12, wherein R^3 is $-L-O-CH_2CH-(C(O)OR^1)(NR^1-TFA)$.
30. The compound of claim 12, wherein R^3 is $-L-OCH_2-C(O)-OR^1$.
- 10 31. The compound of claim 12, wherein R^3 is $-L-CH-(CO_2-alkyl)_2$.
32. The compound of claim 12, wherein R^3 is $-L-CH-(CO_2H)_2$.
- 15 33. The compound of claim 12, wherein R^3 is $-L-SO_2(O-alkyl)$.
34. The compound of claim 12, wherein R^3 is $-L-SO_2(O-aryl)$.
35. The compound of claim 12, wherein R^3 is $-L-SO_3H$.

20


36. The compound of claim 12, wherein R^3 is .

37. The compound of claim 12, wherein R^3 is .


38. The compound of claim 12, wherein R^3 is



39. The compound of claim 12, wherein R^3 is



- 5 40. The compound of claim 12, wherein R^3 is



41. The compound of any of claims 12-40, wherein x is 1, 2, 3, 4, 5, or 6.

42. The compound of any of claims 12-40, wherein x is 1, 2, 3, or 4.

- 10 43. The compound of any of claims 12-40, wherein x is 1 or 2.

44. The compound of any of claims 1-43, wherein m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 15 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100.

45. The compound of any of claims 1-43, wherein m is 1.

- 20 46. The compound of any of claims 1-43, wherein m is 60.

47. The compound of any of claims 1-46, wherein n is 1, 2, or 3.

48. The compound of any of claims 1-46, wherein n is 2.

5 49. The compound of any of claims 1-48, wherein A^1 is an amine protecting group selected from an *N,O*-acetal, allyloxycarbonyl (Aloc), benzyl (Bn), benzyloxycarbonyl (Cbz), benzyloxymethyl (BOM), *t*-butoxycarbonyl (Boc), *t*-butyldimethylsilyl (TBDMS), *t*-butyldiphenylsilyl (TBDPS), diphenylmethyl, diphenylmethyle, ethoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), *p*-methoxybenzyl (PMB), methoxycarbonyl,
10 methoxymethyl (MOM), *p*-methoxyphenyl (PMP), *p*-nitrocinnyloxycarbonyl (Noc), tosyl (Ts), 2-tosylethoxycarbonyl (Tsoc), 2,2,2-trichloroethoxycarbonyl (Troc), trifluoroacetyl, triisopropylsilyl (TIPS), trimethylsilyl (TMS), 2-(trimethylsilyl)ethoxycarbonyl (Teoc), 2-(trimethylsilyl)ethoxymethyl (SEM), or trityl (Tr).

15 50. The compound of any of claims 1-49, wherein A^2 is an -O-(carboxylate protecting group), and the carboxylate protecting group is selected from allyl, benzyl, benzyloxymethyl (BOM), *t*-Bu, *t*-butyldimethylsilyl (TBDMS), *t*-butyldiphenylsilyl (TBDPS), diphenylmethyl, 9-fluorenylmethyl (Fm), 2-methoxyethoxymethyl (MEM), methoxymethyl (MOM), *p*-nitrobenzyl (PNB), an ester, a 1,3-oxazoline, pivaloyloxymethyl (Pom), 2-tosylethyl (TSE),
20 2,2,2-trichloroethyl (TCE), triethylsilyl (TES), trimethylsilyl (TMS), 2-(trimethylsilyl)ethoxymethyl (SEM), or 2-(trimethylsilyl)ethyl (TMSE).


51. The compound of any of claims 1-48, wherein A^1 or A^2 is a protein; and the protein is an antibody.

25

52. The compound of any of claims 1-48, wherein A^1 or A^2 is methionine, or A^1 or A^2 is a peptide comprising a methionine residue, an oligopeptide comprising a methionine residue, a polypeptide comprising a methionine residue, or a protein comprising a methionine residue.

30 53. The compound of any of claims 1-48, wherein A^1 or A^2 is cysteine, or A^1 or A^2 is a peptide comprising a cysteine residue, an oligopeptide comprising a cysteine residue, a polypeptide comprising a cysteine residue, or a protein comprising a cysteine residue.

54. A peptide, an oligopeptide, a polypeptide, or a protein, wherein the peptide, oligopeptide, polypeptide, or protein comprises substructure I



Substructure I

5 wherein,

R^1 is H or alkyl;

R^2 is alkyl;

R^3 is H or substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido;

n is 1-4, inclusive; and

X is a monovalent anion.

15

55. The peptide, oligopeptide, polypeptide, or protein of claim 54, wherein the peptide, oligopeptide, polypeptide, or protein comprises a plurality of substructures I.

56. The peptide, oligopeptide, polypeptide, or protein of claim 54 or claim 55, wherein R^1 is H.

20

57. The peptide, oligopeptide, polypeptide, or protein of claim 54 or claim 55, wherein R^1 is alkyl.

58. The peptide, oligopeptide, polypeptide, or protein of claim 54 or claim 55, wherein R^1 is methyl or ethyl.

25

59. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-58, wherein R² is methyl, ethyl, n-propyl, or n-butyl.

60. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-58, wherein R² is methyl.

61. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-60, wherein R³ is substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido.


62. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-60, wherein R³ is unsubstituted amino, unsubstituted alkyl, unsubstituted alkyloxy, azido, unsubstituted aryl, unsubstituted heteroaryl, halo, unsubstituted allyloxy, unsubstituted alkylcarbonyloxy, unsubstituted phosphonate, unsubstituted carbamate, or unsubstituted amido.

63. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-60, wherein R³ is substituted amino, substituted alkyl, substituted alkyloxy, substituted aryl, substituted heteroaryl, substituted allyloxy, substituted alkylcarbonyloxy, substituted phosphonate, substituted carbamate, or substituted amido.


64. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-60, wherein R³ is substituted alkyloxy.

65. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-60, wherein R³ is heterocycloalkyloxy, phosphonate-substituted alkyloxy, acyloxyalkyloxy, aminoalkyloxy, aminoalkylamidoalkyloxy, or alkyloxycarbonylalkyloxy.

66. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-60, wherein R^3 is -L-halo, -L-azide, -L-NHR¹, -L-NR¹-TFA, -L-NR¹-C(O)-O-alkyl, -L-NR¹-C(O)-CH₂-NR¹-TFA, -L-O-CH₂-CH=CH₂, -L-O-CH₂CCH₃, -L-O-alkyl, -L-O-C(O)-alkyl, -L-P(O)(O-alkyl)₂, -L-P(O)(OH)₂, -L-O-C(O)-C(halo)(alkyl)₂, -L-CH₂-P(O)(O-alkyl)₂, -L-CH₂-P(O)(OH)₂, -L-O-CH₂CH-(C(O)NR¹-alkyl)(NR¹-TFA), -L-O-CH₂CH-(C(O)OR¹)(NR¹-TFA), -L-OCH₂-C(O)-OR¹, -L-CH-(CO₂-alkyl)₂, -L-CH-(CO₂H)₂, -L-SO₂(O-alkyl), -L-SO₂(O-aryl), -L-SO₃H,



67. The peptide, oligopeptide, polypeptide, or protein of claim 66, wherein R^3 is -L-O-alkyl.
68. The peptide, oligopeptide, polypeptide, or protein of claim 66, wherein x is 1, 2, 3, 4, 5, or 6.
69. The peptide, oligopeptide, polypeptide, or protein of claim 66, wherein x is 2, 3, or 4.
70. The peptide, oligopeptide, polypeptide, or protein of claim 66, wherein R^3 is $-(OCH_2CH_2)_3-OCH_3$.
71. The peptide, oligopeptide, polypeptide, or protein of claim 66, wherein R^3 is




72. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-71, wherein n is 1, 2, or 3.

73. The peptide, oligopeptide, polypeptide, or protein of any of claims 54-71, wherein n is 2.

74. A process for chemically modifying a peptide, oligopeptide, polypeptide, or protein by alkylation of one or more thioether groups, comprising the steps of:

contacting a compound of formula II with an aqueous or polar organic solvent



Formula II,

wherein, independently for each occurrence,

R¹ is H or alkyl;

R² is alkyl;

m is 1-200, inclusive;

n is 1-4, inclusive;

A¹ is H, an amine protecting group, a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein;

A² is OH, -O-(a carboxylate protecting group), a natural or unnatural alpha amino acid, a peptide, an oligopeptide, a polypeptide, or a protein;

adding a compound of formula III




Formula III

wherein, independently for each occurrence,

R³ is H or substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted

alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido; and

reacting the compound of formula II with the compound of formula III, thereby creating a compound of formula I



Formula I.

75. The process of claim 74, wherein R^1 is H.

76. The process of claim 74 or claim 75, wherein R^2 is methyl, ethyl, n-propyl, or n-butyl.

77. The process of claim 74 or claim 75, wherein R^2 is methyl.

78. The process of any of claims 74-77, wherein R^3 is substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, azido, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halo, substituted or unsubstituted allyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted phosphonate, substituted or unsubstituted carbamate, or substituted or unsubstituted amido.


79. The process of any of claims 74-77, wherein R^3 is unsubstituted amino, unsubstituted alkyl, unsubstituted alkyloxy, azido, unsubstituted aryl, unsubstituted heteroaryl, halo, unsubstituted allyloxy, unsubstituted alkylcarbonyloxy, unsubstituted phosphonate, unsubstituted carbamate, or unsubstituted amido.

80. The process of any of claims 74-77, wherein R^3 is substituted amino, substituted alkyl, substituted alkyloxy, substituted aryl, substituted heteroaryl, substituted allyloxy, substituted alkylcarbonyloxy, substituted phosphonate, substituted carbamate, or substituted amido.

81. The process of any of claims 74-77, wherein R^3 is substituted alkyloxy.

82. The process of any of claims 74-77, wherein R^3 is heterocycloalkyloxy, phosphonate-substituted alkyloxy, acyloxyalkyloxy, aminoalkyloxy, aminoalkylamidoalkyloxy, or alkyloxycarbonylalkyloxy.

83. The process of any of claims 74-82, wherein R^3 is -L-halo, -L-azide, -L-NHR¹, -L-NR¹-TFA, -L-NR¹-C(O)-O-alkyl, -L-NR¹-C(O)-CH₂-NR¹-TFA, -L-O-CH₂-CH=CH₂, -L-O-CH₂CCH, -L-O-alkyl, -L-O-C(O)-alkyl, -L-P(O)(O-alkyl)₂, -L-P(O)(OH)₂, -L-O-C(O)-C(halo)(alkyl)₂, -L-CH₂-P(O)(O-alkyl)₂, -L-CH₂-P(O)(OH)₂, -L-O-CH₂CH-(C(O)NR¹-alkyl)(NR¹-TFA), -L-O-CH₂CH-(C(O)OR¹)(NR¹-TFA), -L-OCH₂-C(O)-OR¹, -L-CH-(CO₂-alkyl)₂, -L-CH-(CO₂H)₂, -L-SO₂(O-alkyl), -L-SO₂(O-aryl), -L-SO₃H,



L is a bond or $-(OCH_2CH_2)_x-$, and x is 1-10.

84. The process of claim 83, wherein x is 1, 2, 3, 4, 5, or 6.

85. The process of claim 83, wherein x is 2, 3, or 4.

86. The process of any of claims 74-85, wherein m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100.

87. The process of any of claims 74-85, wherein m is 1.

88. The process of any of claims 74-85, wherein m is 60.

89. The process of any of claims 74-88, wherein n is 1, 2, or 3.

90. The process of any of claims 74-88, wherein n is 2.

5 91. The process of any of claims 74-90, wherein A¹ is an amine protecting group selected from an *N,O*-acetal, allyloxycarbonyl (Aloc), benzyl (Bn), benzyloxycarbonyl (Cbz), benzyloxymethyl (BOM), *t*-butoxycarbonyl (Boc), *t*-butyldimethylsilyl (TBDMS), *t*-butyldiphenylsilyl (TBDPS), diphenylmethyl, diphenylmethylene, ethoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), *p*-methoxybenzyl (PMB), methoxycarbonyl,
10 methoxymethyl (MOM), *p*-methoxyphenyl (PMP), *p*-nitrocinnamylloxycarbonyl (Noc), tosyl (Ts), 2-tosylethoxycarbonyl (Tsoc), 2,2,2-trichloroethoxycarbonyl (Troc), trifluoroacetyl, triisopropylsilyl (TIPS), trimethylsilyl (TMS), 2-(trimethylsilyl)ethoxycarbonyl (Teoc), 2-(trimethylsilyl)ethoxymethyl (SEM), or trityl (Tr).

15 92. The process of any of claims 74-90, wherein A¹ is a protein; and the protein is an antibody.

93. The process of any of claims 74-92, wherein A² is an -O-(carboxylate protecting group), and the carboxylate protecting group is selected from allyl, benzyl, benzyloxymethyl
20 (BOM), *t*-Bu, *t*-butyldimethylsilyl (TBDMS), *t*-butyldiphenylsilyl (TBDPS), diphenylmethyl, 9-fluorenylmethyl (Fm), 2-methoxyethoxymethyl (MEM), methoxymethyl (MOM), *p*-nitrobenzyl (PNB), an ester, a 1,3-oxazoline, pivaloyloxymethyl (Pom), 2-tosylethyl (TSE), 2,2,2-trichloroethyl (TCE), triethylsilyl (TES), trimethylsilyl (TMS), 2-(trimethylsilyl)ethoxymethyl (SEM), or 2-(trimethylsilyl)ethyl (TMSE).

25

94. The process of any of claims 74-92, wherein A² is a protein; and the protein is an antibody.

95. The process of any of claims 74-90, wherein A¹ or A² is methionine, or A¹ or A² is a
30 peptide comprising a methionine residue, an oligopeptide comprising a methionine residue, a polypeptide comprising a methionine residue, or a protein comprising a methionine residue.

96. The process of any of claims 74-90, wherein A¹ or A² is cysteine, or A¹ or A² is a peptide comprising a cysteine residue, an oligopeptide comprising a cysteine residue, a polypeptide comprising a cysteine residue, or a protein comprising a cysteine residue.

5 97. The process of any of claims 74-96, wherein the pH of the aqueous or polar organic solvent is less than about 3.

98. The process of any of claims 74-96, wherein the pH of the aqueous or polar organic solvent is about 2.5, about 2.0, about 1.5, about 1.0, or about 0.5.

10

99. The process of any of claims 74-98, wherein the mole ratio of the compound of formula III to the compound of formula II is from about 5:1 to about 1.5:1.

100. The process of any of claims 74-98, wherein the mole ratio of the compound of formula III to the compound of formula II is about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2.5:1, about 2:1, or about 1.5:1, preferably about 3:1, about 2.5:1, about 2:1, or about 1.5:1.

15

101. The process of any of claims 74-100, wherein the temperature of the aqueous or polar organic solvent is from about 20 °C to about 40 °C, for example about 30 °C, about 31 °C, about 32 °C, about 33 °C, about 34 °C, about 35 °C, about 36 °C, about 37 °C, about 38 °C, about 39 °C, or about 40 °C.

20

102. The process of any of claims 74-100, wherein the temperature of the aqueous or polar organic solvent is about 37 °C.

25


103. The process of any of claims 74-102, wherein the aqueous or polar organic solvent is glacial AcOH.

104. A compound formed by the process of any of claims 74-103

30

1/12


FIG. 1



R	Product, Yield	R	Product, Yield
	1, 93%		8, 90%
	2, 95%		9, (74%) ^a
	3, 99%		10, (52%) ^a
	4, 98%		11, (54%) ^a
	5, 90%		
	6, 98%		
	7, 94%		

2/12


FIG. 2



R	Product, Yield	R	Product, Yield
	12 , 99%		15 , 97% ^a
	13 , 89%		16 , 91% ^b
	14 , 90%		17 , 99% ^b

3/12

FIG. 3



M^{EG} (8): $\text{R} = \text{CH}(\text{OH})\text{CH}_2(\text{OCH}_2\text{CH}_2)_3\text{OCH}_3$

M^{N_3} (4): $\text{R} = \text{CH}(\text{OH})\text{CH}_2\text{N}_3$




M^{Me} : $\text{R} = \text{H}$

M^{Bn} : $\text{R} = \text{C}_6\text{H}_5$

Conditions	pH	Dealkylation (mol %)			
		M^{N_3}	M^{EG}	M^{Me}	M^{Bn}
Acetate Buffer	5.0	0	0	0	5
PBS	7.4	0	0	0	5
Borate Buffer	9.0	3	2	0	10
2-Mercaptopyridine	7.4	2	1	0	100

4/12

FIG. 4A



5/12

FIG. 4B







FIG. 4C





7/12

FIG. 5B



8/12

FIG. 6A
















FIG. 6B

Epoxide	Product


9/12

FIG. 6B (continued)

10/12

FIG. 6B (continued)



11/12

FIG. 6B (continued)

[illegible]



 1a-j	 2a-j																																																							
<table><tr><th>Label</th><th>Amino Acid</th><th>Stereo-Isomer^x</th><th>R¹</th><th>R²</th></tr><tr><td>a</td><td>Gly</td><td>—</td><td>H</td><td>H</td></tr><tr><td>b</td><td>Ala</td><td>L</td><td>H</td><td>Me</td></tr><tr><td>c</td><td>Val</td><td>L</td><td>Me</td><td><i>i</i>Pr</td></tr><tr><td>d</td><td>Val</td><td>L</td><td>H</td><td><i>i</i>Pr</td></tr><tr><td>e</td><td>Nle</td><td><i>rac</i></td><td>H</td><td><i>n</i>Bu</td></tr><tr><td>f</td><td>Leu</td><td>L</td><td>H</td><td><i>i</i>Bu</td></tr><tr><td>g</td><td>Phe</td><td>L</td><td>H</td><td>Bn</td></tr><tr><td>h</td><td>Phe</td><td>D</td><td>H</td><td>Bn</td></tr><tr><td>i</td><td>Phe</td><td><i>rac</i></td><td>H</td><td>Bn</td></tr><tr><td>j</td><td>Pgl</td><td>L</td><td>H</td><td>Ph</td></tr></table> x = for marked (*) stereocenter.		Label	Amino Acid	Stereo-Isomer ^x	R ¹	R ²	a	Gly	—	H	H	b	Ala	L	H	Me	c	Val	L	Me	<i>i</i> Pr	d	Val	L	H	<i>i</i> Pr	e	Nle	<i>rac</i>	H	<i>n</i> Bu	f	Leu	L	H	<i>i</i> Bu	g	Phe	L	H	Bn	h	Phe	D	H	Bn	i	Phe	<i>rac</i>	H	Bn	j	Pgl	L	H	Ph
Label	Amino Acid	Stereo-Isomer ^x	R ¹	R ²																																																				
a	Gly	—	H	H																																																				
b	Ala	L	H	Me																																																				
c	Val	L	Me	<i>i</i> Pr																																																				
d	Val	L	H	<i>i</i> Pr																																																				
e	Nle	<i>rac</i>	H	<i>n</i> Bu																																																				
f	Leu	L	H	<i>i</i> Bu																																																				
g	Phe	L	H	Bn																																																				
h	Phe	D	H	Bn																																																				
i	Phe	<i>rac</i>	H	Bn																																																				
j	Pgl	L	H	Ph																																																				

FIG. 6B (continued)

A. CLASSIFICATION OF SUBJECT MATTER**C08G 69/10(2006.01)i, C08G 69/48(2006.01)i, A61K 39/44(2006.01)i, A61K 38/16(2006.01)i, A61K 47/42(2006.01)i, G01N 33/68(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C08G 69/10; C07K 1/02; C07K 1/113; C12Q 1/68; C07H 19/167; C08G 69/48; A61K 39/44; A61K 38/16; A61K 47/42; G01N 33/68

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) STN (CAplus, Registry), Google & Keywords: methionine, peptide, oligopeptide, polypeptide, protein, alkylation, ring opening, epoxide

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ALFERIEV, IVAN S. et al., `High reactivity of alkyl sulfides towards epoxides under conditions of collagen fixation-a convenient approach to 2-amino-4-butyrolactones`, Biomaterials, 2001, Vol. 22, pp. 2501-2506 See abstract; pages 2502, 2505-2506; and Scheme 1.	1-6,54-58,74-77
A	WO 2013-148727 A1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 03 October 2013 See abstract; and paragraphs [0003], [0075], [0078].	1-6,54-58,74-77
A	KRAMER, JESSICA R. et al., `Preparation of Multifunctional and Multireactive Polypeptides via Methionine Alkylation`, Biomacromolecules, 25 May 2012, Vol. 13, No. 6, pp. 1719-1723 See abstract; and Figure 2.	1-6,54-58,74-77
A	US 2011-0177508 A1 (BESTOR, TIMOTHY H. et al.) 21 July 2011 See claims 1-14.	1-6,54-58,74-77
PX	GHARAKHANIAN, ERIC G. et al., `Versatile Synthesis of Stable, Functional Polypeptides via Reaction with Epoxides`, Biomacromolecules, 14 May 2015, Vol. 16, No. 6, pp. 1802-1806 See the whole document.	1-6,54-58,74-77



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 June 2016 (29.06.2016)

Date of mailing of the international search report

29 June 2016 (29.06.2016)

Name and mailing address of the ISA/KR

International Application Division

Korean Intellectual Property Office

189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea

Facsimile No. +82-42-481-8578

Authorized officer

KIM, Dong Seok

Telephone No. +82-42-481-5405



INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US2016/023428**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 13-40, 67-71, 84-85
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Each of claims 13-40, 67-71 and 84-85 refers to a claim which is not drafted in accordance with the third sentence of PCT Rule 6.4(a).
3. ☒ Claims Nos.: 7-12, 41-53, 59-66, 72-73, 78-83, 86-104
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/023428

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2013-148727 A1	03/10/2013	EP 2831090 A1 EP 2831090 A4 US 2015-0057433 A1	04/02/2015 11/11/2015 26/02/2015
US 2011-0177508 A1	21/07/2011	CN 102105483 A DK 2310401 T3 EP 2310401 A1 EP 2310401 A4 EP 2310401 B1 US 2015-148240 A1 WO 2010-011312 A1 WO 2010-011312 A9	22/06/2011 29/02/2016 20/04/2011 02/05/2012 25/11/2015 28/05/2015 28/01/2010 29/04/2010